Publications

Journals

• Nutt D. (27 Jan 2012). Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. Curr Opin Pharmacol. DOI.
• Tyacke RJ; Fisher A; Robinson ES; Grundt P; Turner EM; Husbands SM; Hudson AL; Parker CA; et alNutt DJ. (31 Jan 2012). Evaluation and initial in vitro and ex vivo characterisation of the potential positron emission tomography ligand, BU99008 (2-(4,5-Dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the Imidazoline(2) binding site. Synapse. DOI.
• Nutt DJ; Lingford-Hughes A; Chick J. (Feb 2012). Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?. J Psychopharmacol. 26:199-204. DOI.
• Nutt D. (Nov 2011). Low serotonergic tone and elevated risk for substance misuse. BRIT J PSYCHIAT. 199:353-354. DOI.
• Stone JM; Dietrich C; Edden R; Mehta MA; De Simoni S; Reed LJ; Krystal JH; Nutt D; et alBarker GJ. (3 Jan 2012). Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. DOI.
• Nutt DJ. (Oct 2011). The full cost and burden of disorders of the brain in Europe exposed for the first time. EUR NEUROPSYCHOPHARM. 21:715-717. DOI.
• Kalk NJ; Melichar J; Holmes RB; Taylor LG; Daglish MR; Hood S; Edwards T; Lennox-Smith A; et alLingford-Hughes AR; Nutt DJ. (17 Sep 2011). Central noradrenergic responsiveness to a clonidine challenge in Generalized Anxiety Disorder: a Single Photon Emission Computed Tomography study. J Psychopharmacol. DOI.
• Nutt D. (Nov 2011). Let not the best be the enemy of the good. Addiction. 106:1892-1893. DOI.
• Stokes PR; Egerton A; Watson B; Reid A; Lappin J; Howes OD; Nutt DJ; Lingford-Hughes AR. (Jan 2012). History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol. 26:144-149. DOI.
• Bailey JE; Papadopoulos A; Diaper A; Phillips S; Schmidt ME; van der Ark P; Dourish CT; Dawson GR; et alNutt DJ. (Sep 2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. J PSYCHOPHARMACOL. 25:1199-1206. DOI.
• Bailey JE; Dawson GR; Dourish CT; Nutt DJ. (Sep 2011). Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). J PSYCHOPHARMACOL. 25:1192-1198. DOI.
• Watson BJ; Wilson S; Griffin L; Kalk NJ; Taylor LG; Munafo MR; Lingford-Hughes AR; Nutt DJ. (Jul 2011). A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. PSYCHOPHARMACOLOGY. 216:121-129. DOI.
• Paterson LM; Kornum BR; Nutt DJ; Pike VW; Knudsen GM. (14 Jun 2011). 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. DOI.
• Nutt DJ. (Jun 2011). Highlights of the international consensus statement on major depressive disorder. J Clin Psychiatry. 72:e21. DOI.
• Lewis G; Mulligan J; Wiles N; Cowen P; Craddock N; Ikeda M; Grozeva D; Mason V; et alNutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Peters TJ. (Jun 2011). Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. BRIT J PSYCHIAT. 198:464-471. DOI.
• Amara SG; Grillner S; Insel T; Nutt D; Tsumoto T. (May 2011). Neuroscience in recession?. NAT REV NEUROSCI. 12:297-+. DOI.
• Paterson LM; Nutt DJ; Wilson SJ. (Sep 2011). Sleep and its disorders in translational medicine. J Psychopharmacol. 25:1226-1234. DOI.
• Carhart-Harris RL; King LA; Nutt DJ. (1 Oct 2011). A web-based survey on mephedrone. Drug Alcohol Depend. 118:19-22. DOI.
• Nutt D; Phillips L; King L. (12 Feb 2011). Drugs and harm to society reply. LANCET. 377:555-555.
• Cooper RM; Bailey JE; Diaper A; Stirland R; Renton LE; Benton CP; Penton-Voak IS; Nutt DJ; et alMunafo MR. (2011). Effects of 7.5% CO2 inhalation on allocation of spatial attention to facial cues of emotional expression. COGNITION EMOTION. 25:626-638. DOI.
• Nutt DJ. (2011). NHS drug budget. Flawed assumption in analysis. BMJ. 342:d448.
• Kealey S; Husbands SM; Casey E; Salinas CA; Parker CA; Jakobsen S; Tyacke RJ; Nutt DJ; et alGee AD. (2011). Synthesis and in vivo evaluation of [C-11]BU99008 as a ligand for the imidazoline I-2 binding site. J LABELLED COMPD RAD. 54:S304-S304.
• Nutt D. (Jan 2011). Synthetic Spirits. SCIENTIST. 25:23-23.
• Maron E; Tõru I; Hirvonen J; Tuominen L; Lumme V; Vasar V; Shlik J; Nutt DJ; et alHelin S; Någren K; Tiihonen J; Hietala J. (Jul 2011). Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol. 25:952-959. DOI.
• Owen DR; Lewis AJ; Reynolds R; Rupprecht R; Eser D; Wilkins MR; Bennacef I; Nutt DJ; et alParker CA. (Mar 2011). Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse. 65:257-259. DOI.
• Wilson SJ; Nutt DJ; Alford C; Argyropoulos SV; Baldwin DS; Bateson AN; Britton TC; Crowe C; et alDijk DJ; Espie CA; Gringras P; Hajak G; Idzikowski C; Krystal AD; Nash JR; Selsick H; Sharpley AL; Wade AG. (Nov 2010). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J PSYCHOPHARMACOL. 24:1577-1600. DOI.
• Nutt DJ; King LA; Phillips LD; Independent Scientific Committee on Drugs. (6 Nov 2010). Drug harms in the UK: a multicriteria decision analysis. Lancet. 376:1558-1565. DOI.
• Christmas DM; Badawy AAB; Hince D; Davies SJC; Probert C; Creed T; Smithson J; Afzal M; et alNutt DJ; Potokar JP. (Oct 2010). Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. NUTR RES. 30:678-688. DOI.
• Lingford-Hughes A; Reid AG; Myers J; Feeney A; Hammers A; Taylor LG; Rosso L; Turkheimer F; et alBrooks DJ; Grasby P; Nutt DJ. (Feb 2012). A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions. J Psychopharmacol. 26:273-281. DOI.
• Rogers PJ; Hohoff C; Heatherley SV; Mullings EL; Maxfield PJ; Evershed RP; Deckert J; Nutt DJ. (Aug 2010). Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption. NEUROPSYCHOPHARMACOL. 35:1973-1983. DOI.
• Deakin B; Ferrier N; Holt RIG; Millar H; Nutt DJ; Reynolds G; Samani N; Taylor D. (Aug 2010). The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. J PSYCHOPHARMACOL. 24:1-8. DOI.
• Nutt DJ; Feetam CL. (Aug 2010). What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. J Psychopharmacol. 24:1137-1141. DOI.
• Wood E; Werb D; Kazatchkine M; Kerr T; Hankins C; Gorna R; Nutt D; Des Jarlais D; et alBarré-Sinoussi F; Montaner J. (31 Jul 2010). Vienna Declaration: a call for evidence-based drug policies. Lancet. 376:310-312. DOI.
• Paterson LM; Tyacke RJ; Nutt DJ; Knudsen GM. (Oct 2010). Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab. 30:1682-1706. DOI.
• Garcia de Miguel B; Nutt D; Hood SD; Davies SJ. (19 Jul 2010). Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. J Psychopharmacol. DOI.
• Nutt D. (Jul 2010). Science and non-science in UK drug policy. Addiction. 105:1154. DOI.
• Colasanti A; Rabiner EA; Lingford-Hughes A; Nutt DJ. (Nov 2011). Opioids and anxiety. J Psychopharmacol. 25:1415-1433. DOI.
• Kalk NJ; Nutt DJ; Lingford-Hughes AR. (Jan 2011). The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol. 25:3-16. DOI.
• Papadopoulos A; Chandramohan Y; Collins A; Droste SK; Nutt DJ; Reul JM. (Apr 2011). GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. Eur Neuropsychopharmacol. 21:316-324. DOI.
• Baldwin DS; Allgulander C; Altamura AC; Angst J; Bandelow B; den Boer J; Boyer P; Davies S; et alDell'Osso B; Eriksson E; Fineberg N; Fredrikson M; Herran A; Maron E; Metspalu A; Nutt D; van der Wee N; Vazquez-Barquero JL; Zohar J. (Jun 2010). Manifesto for a European Anxiety Disorders Research Network. EUR NEUROPSYCHOPHARM. 20:426-432. DOI.
• Guloksuz S; Cetin EA; Cetin T; Deniz G; Oral ET; Nutt DJ. (Nov 2010). Cytokine levels in euthymic bipolar patients. J Affect Disord. 126:458-462. DOI.
• Stokes PR; Egerton A; Watson B; Reid A; Breen G; Lingford-Hughes A; Nutt DJ; Mehta MA. (1 Oct 2010). Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage. 52:1521-1527. DOI.
• Davies SJ; Esler M; Nutt DJ. (May 2010). Anxiety--bridging the heart/mind divide. J Psychopharmacol. 24:633-638. DOI.
• Hood SD; Potokar JP; Davies SJ; Hince DA; Morris K; Seddon KM; Nutt DJ; Argyropoulos SV. (May 2010). Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. J Psychopharmacol. 24:709-716. DOI.
• Papadopoulos A; Rich A; Nutt DJ; Bailey JE. (May 2010). The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. J Psychopharmacol. 24:649-656. DOI.
• Hill LE; Droste SK; Nutt DJ; Linthorst AC; Reul JM. (May 2010). Voluntary exercise alters GABA(A) receptor subunit and glutamic acid decarboxylase-67 gene expression in the rat forebrain. J Psychopharmacol. 24:745-756. DOI.
• Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ. (Nov 2011). The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol. 25:1562-1567. DOI.
• Seddon K; Morris K; Bailey J; Potokar J; Rich A; Wilson S; Bettica P; Nutt DJ. (Jan 2011). Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol. 25:43-51. DOI.
• Nutt D. (27 Feb 2010). Nutt damage reply. LANCET. 375:724-724.
• Nutt DJ. (Feb 2010). Antagonist-agonist combinations as therapies for heroin addiction: back to the future?. J Psychopharmacol. 24:141-145. DOI.
• Hood SD; Hince DA; Davies SJC; Argyropoulos S; Robinson H; Potokar J; Nutt DJ. (Feb 2010). Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. PSYCHOPHARMACOLOGY. 208:223-232. DOI.
• Morgan CJA; Muetzelfeldt L; Muetzelfeldt M; Nutt DJ; Curran HV. (Feb 2010). Harms associated with psychoactive substances: findings of the UK National Drug Survey. J PSYCHOPHARMACOL. 24:147-153. DOI.
• Zhang LH; Gough J; Christmas D; Mattey DL; Richards SCM; Main J; Enlander D; Honeybourne D; et alAyres JG; Nutt DJ; Kerr JR. (Feb 2010). Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J CLIN PATHOL. 63:156-164. DOI.
• Corrigan FM; Fisher JJ; Nutt DJ. (Jan 2011). Autonomic dysregulation and the Window of Tolerance model of the effects of complex emotional trauma. J Psychopharmacol. 25:17-25. DOI.
• Hood SD; Melichar JK; Taylor LG; Kalk N; Edwards TR; Hince DA; Lenox-Smith A; Lingford-Hughes AR; et alNutt DJ. (Jan 2011). Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol. 25:78-86. DOI.
• Davidson JR; Zhang W; Connor KM; Ji J; Jobson K; Lecrubier Y; McFarlane AC; Newport DJ; et alNutt DJ; Osser DN; Stein DJ; Stowe ZN; Tajima O; Versiani M. (Jan 2010). A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). J Psychopharmacol. 24:3-26. DOI.
• Maron E; Nutt DJ; Kuikka J; Tiihonen J. (Jan 2010). Dopamine transporter binding in females with panic disorder may vary with clinical status. J PSYCHIATR RES. 44:56-59. DOI.
• Tyacke RJ; Lingford-Hughes A; Reed LJ; Nutt DJ. (2010). GABAB receptors in addiction and its treatment. Adv Pharmacol. 58:373-396. DOI.
• Nutt DJ; Davidson JR; Gelenberg AJ; Higuchi T; Kanba S; Karamustafalioğlu O; Papakostas GI; Sakamoto K; et alTerao T; Zhang M. (2010). International consensus statement on major depressive disorder. J Clin Psychiatry. 71 Suppl E1:e08. DOI.
• Nutt DJ. (2010). Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. J Clin Psychiatry. 71 Suppl E1:e02. DOI.
• Carhart-Harris RL; Nutt DJ. (2010). User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. J SUBST USE. 15:283-300. DOI.
• Nutt D. (5 Dec 2009). Nutt controversy Reply. NEW SCI. 204:30-30.
• Bolea-Alamanac BM; Davies SJ; Christmas DM; Baxter H; Cullum S; Nutt DJ. (Jan 2011). Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. J Psychopharmacol. 25:141-145. DOI.
• Nutt DJ; Stahl SM. (Nov 2010). Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 24:1601-1612. DOI.
• Nutt D. (21 Nov 2009). Government vs science over drug and alcohol policy. Lancet. 374:1731-1733. DOI.
• Nutt D. (7 Nov 2009). A dangerous attitude to drugs. NEW SCI. 204:5-5.
• Nutt D; Mandel F; Baldinetti F. (Nov 2009). Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol. 23:867-873. DOI.
• Nutt DJ. (Nov 2009). Prescribing antidepressants post Cipriani et al. J PSYCHOPHARMACOL. 23:865-866. DOI.
• Bell C; Hood S; Potokar J; Nash J; Adrover M; Frampton C; Hince D; Rich A; et alArgyropoulos S; Nutt D. (Feb 2011). Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. Psychopharmacology (Berl). 213:593-602. DOI.
• Williams TM; Davies SJ; Taylor LG; Daglish MR; Hammers A; Brooks DJ; Nutt DJ; Lingford-Hughes A. (Oct 2009). Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 19:740-748. DOI.
• Carhart-Harris RL; Nutt DJ; Munafo MR; Christmas DM; Wilson SJ. (Oct 2009). Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. Psychopharmacology (Berl). 206:187-196. DOI.
• Tolchard S; Burns PA; Nutt DJ; Fitzjohn SM. (Oct 2009). Hypothermic responses to infection are inhibited by alpha2-adrenoceptor agonists with possible clinical implications. Br J Anaesth. 103:554-560. DOI.
• Nutt DJ. (Sep 2009). Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? (vol 23, pg 343, 2009). J PSYCHOPHARMACOL. 23:861-861. DOI.
• Argyropoulos SV; Hicks JA; Nash JR; Bell CJ; Rich AS; Nutt DJ; Wilson S. (Sep 2009). Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. J Sleep Res. 18:342-348. DOI.
• Kimura A; Tyacke RJ; Robinson JJ; Husbands SM; Minchin MC; Nutt DJ; Hudson AL. (7 Jul 2009). Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res. 1279:21-28. DOI.
• Araya R; Hu X; Heron J; Enoch MA; Evans J; Lewis G; Nutt D; Goldman D. (5 Jul 2009). Effects of stressful life events, maternal depression and 5-HTTLPR genotype on emotional symptoms in pre-adolescent children. Am J Med Genet B Neuropsychiatr Genet. 150B:670-682. DOI.
• Paterson LM; Wilson SJ; Nutt DJ; Hutson PH; Ivarsson M. (Jul 2009). Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. J Psychopharmacol. 23:475-486. DOI.
• Maron E; Eller T; Vasar V; Nutt DJ. (Jul 2009). Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. J Clin Psychiatry. 70:1054-1056.
• Paterson LM; Nutt DJ; Ivarsson M; Hutson PH; Wilson SJ. (Jul 2009). Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. J PSYCHOPHARMACOL. 23:487-494. DOI.
• Corchs F; Nutt DJ; Hood S; Bernik M. (1 Jul 2009). Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. Biol Psychiatry. 66:17-24. DOI.
• Sinclair LI; Christmas DM; Hood SD; Potokar JP; Robertson A; Isaac A; Srivastava S; Nutt DJ; et alDavies SJ. (Jun 2009). Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 194:483-490. DOI.
• Nutt DJ. (Jun 2009). Beyond psychoanaleptics - can we improve antidepressant drug nomenclature?. J PSYCHOPHARMACOL. 23:343-345. DOI.
• Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A. (Jun 2009). Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 19:451-456. DOI.
• Lowry CA; Lightman SL; Nutt DJ. (Jun 2009). That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. J Psychopharmacol. 23:392-400. DOI.
• Hood SD; Davies SJ; Nutt DJ. (May 2009). Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al. Psychopharmacology (Berl). 203:831-833. DOI.
• Carhart-Harris RL; Nutt DJ; Munafò M; Wilson SJ. (May 2009). Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. J Psychopharmacol. 23:249-257. DOI.
• Munafò M; Bailey J; Diaper A; Cooper R; Benton C; Penton-Voak I; Nutt D. (13 Mar 2009). RETRACTION: Effects of 7.5% CO2 inhalation on allocation of spatial attention to facial cues of emotional expression. J Psychopharmacol. DOI.
• Evans J; Xu K; Heron J; Enoch MA; Araya R; Lewis G; Timpson N; Davies S; et alNutt D; Goldman D. (5 Mar 2009). Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. Am J Med Genet B Neuropsychiatr Genet. 150B:209-218. DOI.
• Bailey JE; Papadopoulos A; Seddon K; Nutt DJ. (Mar 2009). A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. J Psychopharmacol. 23:117-122. DOI.
• Nutt DJ; Attridge J. (Mar 2009). Innovation Processes in Psychopharmacology and the Implications for Assessing the Relative Effectiveness of New Medicines. J MENT HEALTH POLICY. 12:S32-S32.
• Nutt D. (2009). Changes in neurotransmission in relation to early treatment and outcome in depression. INT J PSYCHIAT CLIN. 13:21-21.
• Stein DJ; Cloitre M; Nemeroff CB; Nutt DJ; Seedat S; Shalev AY; Wittchen HU; Zohar J. (Jan 2009). Cape Town consensus on posttraumatic stress disorder. CNS Spectr. 14:52-58.
• Nutt DJ. (Jan 2009). Equasy-- an overlooked addiction with implications for the current debate on drug harms. J Psychopharmacol. 23:3-5. DOI.
• Paterson LM; Nutt DJ; Wilson SJ. (2009). NAPSAQ-1: National Patient Sleep Assessment Questionnaire in depression. INT J PSYCHIAT CLIN. 13:48-58. DOI.
• Shufflebotham J; Wetherell MA; Hince D; Hood S; Lightman S; Nutt D; Probert C; Potokar J. (2009). Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. Stress. 12:30-36. DOI.
• Davies SJ; Jackson PR; Lewis G; Hood SD; Nutt DJ; Potokar JP. (Dec 2008). Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. J Affect Disord. 111:344-350. DOI.
• Taylor C; Nash J; Rich A; Lingford-Hughes A; Nutt D; Potokar J. (Nov 2008). Assessment of GABAA benzodiazepine receptor (GBzR) sensitivity in patients with alcohol dependence. Alcohol Alcohol. 43:614-618. DOI.
• Sessa B; Nutt DJ. (Nov 2008). MDMA, politics and medical research: have we thrown the baby out with the bathwater? (vol 21, pg 787, 2007). J PSYCHOPHARMACOL. 22:932-932. DOI.
• Robbins TW; Everitt BJ; Nutt DJ. (12 Oct 2008). Introduction. The neurobiology of drug addiction: new vistas. Philos Trans R Soc Lond B Biol Sci. 363:3109-3111. DOI.
• Wilson S; Nutt D. (Sep 2008). Drug treatment of chronic insomnia -- dawn at the end of a long night?. J Psychopharmacol. 22:703-706. DOI.
• Nash JR; Sargent PA; Rabiner EA; Hood SD; Argyropoulos SV; Potokar JP; Grasby PM; Nutt DJ. (Sep 2008). Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. BRIT J PSYCHIAT. 193:229-234. DOI.
• Daglish MRC; Williams TM; Wilson SJ; Taylor LG; Eap CB; Augsburger M; Giroud C; Brooks DJ; et alMyles JS; Grasby P; Lingford-Hughes AR; Nutt DJ. (Jul 2008). Brain dopamine response in human opioid addiction. BRIT J PSYCHIAT. 193:65-72. DOI.
• Hickman M; Lingford-Hughes A; Bailey C; Macleod J; Nutt D; Henderson G. (Jul 2008). Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction. 103:1060-1062. DOI.
• Bailey JE; Nutt DJ. (Jul 2008). GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?. Pharmacol Biochem Behav. 90:51-57. DOI.
• Reul JM; Nutt DJ. (Jul 2008). Glutamate and cortisol--a critical confluence in PTSD?. J Psychopharmacol. 22:469-472. DOI.
• Hickman M; Lingford-Hughes A; Bailey C; Macleod J; Nutt D; Henderson G. (Jul 2008). Understanding causal pathways: A response to the commentaries. ADDICTION. 103:1067-1068.
• Allgulander C; Nutt D; Detke M; Erickson J; Spann M; Walker D; Ball SG; Russell JM. (Jun 2008). A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol. 22:417-425. DOI.
• Nutt D; Allgulander C; Lecrubier Y; Peters T; Wittchen U. (Jun 2008). Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. J Psychopharmacol. 22:409-416. DOI.
• Sessa B; Nutt D. (Jun 2008). Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with the bath water) in the November 2007 journal. J Psychopharmacol. 22:457-458. DOI.
• Kerr JR; Burke B; Petty R; Gough J; Fear D; Mattey DL; Axford JS; Dalgleish AG; et alNutt DJ. (Jun 2008). Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol. 61:730-739. DOI.
• Allgulander C; Nutt DJ. (Jun 2008). Wine and drug evaluations: lessons on making comparisons of noninferiority. J Psychopharmacol. 22:341-342. DOI.
• Nutt D; Lingford-Hughes A. (May 2008). Addiction: the clinical interface. Br J Pharmacol. 154:397-405. DOI.
• Nutt D. (May 2008). Reply to OCD letter. J Psychopharmacol. 22:338.
• Nutt D. (May 2008). Untitled - Reply to OCD letter. J PSYCHOPHARMACOL. 22:338-338. DOI.
• Nutt DJ; Malizia AL. (May 2008). Why does the world have such a 'down' on antidepressants?. J Psychopharmacol. 22:223-226. DOI.
• Nutt DJ. (Apr 2008). Shifting schizophrenia treatment paradigms: The scope for adjunctive therapies. EUR PSYCHIAT. 23:S11-S11.
• Hitsman B; MacKillop J; Lingford-Hughes A; Williams TM; Ahmad F; Adams S; Nutt DJ; Munafò MR. (Mar 2008). Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl). 196:611-621. DOI.
• Trivedi MH; Hollander E; Nutt D; Blier P. (Feb 2008). Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 69:246-258.
• Thomas L; Mulligan J; Mason V; Tallon D; Wiles N; Cowen P; Nutt D; O'Donovan M; et alSharp D; Peters T; Lewis G. (2008). GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials. 9:29. DOI.
• Carhart-Harris RL; Mayberg HS; Malizia AL; Nutt D. (2008). Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. Ann Gen Psychiatry. 7:9. DOI.
• Christmas D; Hood S; Nutt D. (2008). Potential novel anxiolytic drugs. Curr Pharm Des. 14:3534-3546.
• Reid AG; Daglish MRC; Kempton MJ; Williams TM; Watson B; Nutt DJ; Lingford-Hughes AR. (Jan 2008). Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. J PSYCHOPHARMACOL. 22:7-10. DOI.
• Nutt DJ. (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 69 Suppl E1:4-7.
• Nutt D; Wilson S; Paterson L. (2008). Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 10:329-336.
• Nutt DJ; Sharpe M. (Jan 2008). Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol. 22:3-6. DOI.
• Nutt DJ; Besson M; Wilson SJ; Dawson GR; Lingford-Hughes AR. (Dec 2007). Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology. 53:810-820. DOI.
• Sessa B; Nutt DJ. (Nov 2007). MDMA, politics and medical research: have we thrown the baby out with the bathwater?. J Psychopharmacol. 21:787-791. DOI.
• Montgomery SA; Baldwin DS; Blier P; Fineberg NA; Kasper S; Lader M; Lam RW; Lépine JP; et alMöller HJ; Nutt DJ; Rouillon F; Schatzberg AF; Thase ME. (Nov 2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 22:323-329. DOI.
• Bailey JE; Papadopoulos A; Lingford-Hughes A; Nutt DJ. (Sep 2007). D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology (Berl). 193:579-585. DOI.
• Wilson S; Nutt D. (Sep 2007). Management of insomnia: treatments and mechanismsi. Br J Psychiatry. 191:195-197. DOI.
• Hume SP; Lingford-Hughes AR; Nataf V; Hirani E; Ahmad R; Davies AN; Nutt DJ. (Aug 2007). Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates. J Pharmacol Exp Ther. 322:661-667. DOI.
• Nutt D. (Aug 2007). Media care and patient pressure - Reply. J PSYCHOPHARMACOL. 21:670-670.
• Davies SJ; Lowry CA; Nutt DJ. (Aug 2007). Panic and hypertension: brothers in arms through 5-HT?. J Psychopharmacol. 21:563-566. DOI.
• Montgomery AJ; Lingford-Hughes AR; Egerton A; Nutt DJ; Grasby PM. (Aug 2007). The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse. 61:637-645. DOI.
• King LA; Nutt D. (21 Jul 2007). Seizures in a night club. Lancet. 370:220. DOI.
• Abu Ghazaleh H; Lalies MD; Husbands SM; Nutt DJ; Hudson AL. (11 Jul 2007). The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. Neurosci Lett. 422:109-113. DOI.
• Williams TM; Daglish MRC; Lingford-Hughes A; Taylor LG; Hammers A; Brooks DJ; Grasby P; Myles JS; et alNutt DJ. (Jul 2007). Brain opioid receptor binding in early abstinence from opioid dependence - Positron emission tomography study. BRIT J PSYCHIAT. 191:63-69. DOI.
• Nutt D; Demyttenaere K; Janka Z; Aarre T; Bourin M; Canonico PL; Carrasco JL; Stahl S. (Jul 2007). The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 21:461-471. DOI.
• Nutt D; King L; Saulsbury W; Blakemore C. (2 Jun 2007). Assessing drug-related harm - Reply. LANCET. 369:1857-1857.
• Paterson LM; Wilson SJ; Nutt DJ; Hutson PH; Ivarsson M. (May 2007). A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. PSYCHOPHARMACOLOGY. 191:943-950. DOI.
• Nutt D; King LA; Saulsbury W; Blakemore C. (24 Mar 2007). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 369:1047-1053. DOI.
• Argyropoulos SV; Ploubidis GB; Wright TS; Palm ME; Hood SD; Nash JR; Taylor AC; Forshall SW; et alAnderson IM; Nutt DJ; Potokar JP. (Mar 2007). Development and validation of the Generalized Anxiety Disorder Inventory (GADI). J Psychopharmacol. 21:145-152. DOI.
• Kerr JR; Christian P; Hodgetts A; Langford PR; D Devanur L; Petty R; Burke B; Sinclair LI; et alRichards SCM; Montgomery J; McDermott CR; Harrison TJ; Kellam P; Nutt DJ; Holgate ST; Clinical Study Grp. (Feb 2007). Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments. J CLIN PATHOL. 60:113-116. DOI.
• Paterson LM; Tyacke RJ; Robinson ES; Nutt DJ; Hudson AL. (Feb 2007). In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: evidence for two distinct I2 binding sites. Neuropharmacology. 52:395-404. DOI.
• Bailey JE; Kendrick A; Diaper A; Potokar JP; Nutt DJ. (Jan 2007). A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol. 21:42-49. DOI.
• Nutt DJ; Kessler RC; Alonso J; Benbow A; Lecrubier Y; Lépine JP; Mechanic D; Tylee A. (2007). Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety. J Clin Psychiatry. 68 Suppl 2:42-48.
• Nutt D. (Jan 2007). Ecstasy versus alcohol: Tolstoy and the variations of unhappiness - Reply from the Editor. J PSYCHOPHARMACOL. 21:7-7. DOI.
• Nutt DJ; Fone K; Asherson P; Bramble D; Hill P; Matthews K; Morris KA; Santosh P; et alSonuga-Barke E; Taylor E; Weiss M; Young S; British Association for Psychopharmacology. (Jan 2007). Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 21:10-41. DOI.
• Kalueff AV; Nutt DJ. (2007). Role of GABA in anxiety and depression. Depress Anxiety. 24:495-517. DOI.
• Papakostas GI; Nutt DJ; Hallett LA; Tucker VL; Krishen A; Fava M. (15 Dec 2006). Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 60:1350-1355. DOI.
• Heath TP; Melichar JK; Nutt DJ; Donaldson LF. (6 Dec 2006). Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci. 26:12664-12671. DOI.
• Robinson HM; Hood SD; Bell CJ; Nutt DJ. (Dec 2006). Dopamine and social anxiety disorder. Rev Bras Psiquiatr. 28:263-264.
• Shufflebotham J; Hood S; Hendry J; Hince DA; Morris K; Nutt D; Probert C; Potokar J. (Nov 2006). Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol. 101:2582-2587. DOI.
• Nutt D; Malizia A. (Nov 2006). Anxiety and OCD - the chicken or the egg?. J Psychopharmacol. 20:729-731. DOI.
• Saczewski F; Tabin P; Tyacke RJ; Maconie A; Saczewski J; Kornicka A; Nutt DJ; Hudson AL. (1 Oct 2006). 2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic alpha2 receptor ligands. Bioorg Med Chem. 14:6679-6685. DOI.
• Nutt DJ; Stein DJ. (Oct 2006). Understanding the neurobiology of comorbidity in anxiety disorders. CNS Spectr. 11:13-20.
• Davies SJC; Hood SD; Argyropoulos SV; Morris K; Bell C; Witchel HJ; Jackson PR; Nutt DJ; et alPotokar JP. (Aug 2006). Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J CLIN PSYCHOPHARM. 26:414-418. DOI.
• Davies SJ; Hood SD; Argyropoulos SV; Morris K; Bell C; Witchel HJ; Jackson PR; Nutt DJ; et alPotokar JP. (Aug 2006). Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J Clin Psychopharmacol. 26:414-418. DOI.
• Papadopoulos V; Baraldi M; Guilarte TR; Knudsen TB; Lacapère JJ; Lindemann P; Norenberg MD; Nutt D; et alWeizman A; Zhang MR; Gavish M. (Aug 2006). Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 27:402-409. DOI.
• Nutt D. (Aug 2006). What we know and what we don't know about how antipsychotics work. AUST NZ J PSYCHIAT. 40:A106-A106.
• Nutt D; Argyropoulos S; Hood S; Potokar J. (Jul 2006). Generalized anxiety disorder: A comorbid disease. Eur Neuropsychopharmacol. 16 Suppl 2:S109-S118. DOI.
• Nutt DJ; Baldwin DS; Clayton AH; Elgie R; Lecrubier Y; Montejo AL; Papakostas GI; Souery D; et alTrivedi MH; Tylee A. (2006). The role of dopamine and norepinephrine in depression and antidepressant treatment. J CLIN PSYCHIAT. 67:46-49.
• Nutt DJ. (May 2006). A tale of two Es. J Psychopharmacol. 20:315-317. DOI.
• Nutt DJ. (May 2006). Alcohol alternatives--a goal for psychopharmacology?. J Psychopharmacol. 20:318-320. DOI.
• Nutt D. (May 2006). Harm reduction: lessons learned from tobacco control - Reply to commentaries. J PSYCHOPHARMACOL. 20:331-331. DOI.
• Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ. (May 2006). Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology (Berl). 186:107-112. DOI.
• Nutt D. (15 Apr 2006). GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med. 2:S7-11.
• Anderson NJ; Seif I; Nutt DJ; Hudson AL; Robinson ES. (Mar 2006). Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem. 96:1551-1559. DOI.
• Lingford-Hughes AR; Daglish MRC; Stevenson BJ; Feeney A; Pandit SA; Wilson SJ; Myles J; Grasby PM; et alNutt DJ. (Mar 2006). Imaging alcohol cue exposure in alcohol dependence using a PET O-15-H2O paradigm: results from a pilot study. ADDICT BIOL. 11:107-115. DOI.
• Anderson NJ; Tyacke RJ; Husbands SM; Nutt DJ; Hudson AL; Robinson ES. (Mar 2006). In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology. 50:269-276. DOI.
• Nutt DJ; Baldwin DS; Clayton AH; Elgie R; Lecrubier Y; Montejo AL; Papakostas GI; Souery D; et alTrivedi MH; Tylee A. (2006). Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 67 Suppl 6:46-49.
• Nutt DJ. (Jan 2006). Informed consent--a new approach to drug regulation?. J Psychopharmacol. 20:3-4. DOI.
• Nutt DJ. (2006). The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 67 Suppl 6:3-8.
• Ruddick JP; Evans AK; Nutt DJ; Lightman SL; Rook GA; Lowry CA. (2006). Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 8:1-27. DOI.
• Baldwin DS; Anderson IM; Nutt DJ; Bandelow B; Bond A; Davidson JR; den Boer JA; Fineberg NA; et alKnapp M; Scott J; Wittchen HU; British Association for Psychopharmacology. (Nov 2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 19:567-596. DOI.
• Davies SJ; Pandit SA; Feeney A; Stevenson BJ; Kerwin RW; Nutt DJ; Marshall EJ; Boddington S; et alLingford-Hughes A. (Nov 2005). Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence?. Alcohol Alcohol. 40:498-503. DOI.
• Kornicka A; Saczewski F; Tyacke RJ; Hudson AL; Nutt DJ. (Nov 2005). Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-ols. Acta Pol Pharm. 62:497-502.
• Wilson SJ; Bailey JE; Rich AS; Nash J; Adrover M; Tournoux A; Nutt DJ. (Nov 2005). The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol. 19:609-613. DOI.
• Anderson NJ; Lupo PA; Nutt DJ; Hudson AL; Robinson ES. (5 Sep 2005). Characterisation of imidazoline I2 binding sites in pig brain. Eur J Pharmacol. 519:68-74. DOI.
• Nutt DJ. (Sep 2005). Dr Shipman's last legacy: e-surveillance of the medical profession. J Psychopharmacol. 19:441. DOI.
• Robinson ES; Nutt DJ; Jackson HC; Hudson AL. (30 Aug 2005). The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo. J Neurosci Methods. 147:48-54. DOI.
• Lingford-Hughes A; Wilson SJ; Feeney A; Grasby PG; Nutt DJ. (Aug 2005). A proof-of-concept study using [C-11]flumazenil PET to demonstrate that pagoclone is a partial agonist. PSYCHOPHARMACOLOGY. 180:789-791. DOI.
• Robbins TW; Nutt DJ; de Wit H. (Aug 2005). Brain imaging - Editorial. PSYCHOPHARMACOLOGY. 180:581-582. DOI.
• Lingford-Hughes AR; Wilson SJ; Cunningham VJ; Feeney A; Stevenson B; Brooks DJ; Nutt DJ. (Aug 2005). GABA-benzodiazepine receptor function in alcohol dependence: a combined C-11-flumazenil PET and pharmacodynamic study. PSYCHOPHARMACOLOGY. 180:595-606. DOI.
• Hood SD; Bell CJ; Nutt DJ. (Jul 2005). Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry. 39:558-564. DOI.
• Bell CJ; Hood SD; Nutt DJ. (Jul 2005). Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry. 39:565-574. DOI.
• Slattery DA; Morrow JA; Hudson AL; Hill DR; Nutt DJ; Henry B. (Jul 2005). Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology. 30:1278-1287. DOI.
• Nutt DJ. (Jul 2005). Foresight brain science, addiction and drugs project. J Psychopharmacol. 19:325. DOI.
• Wilson SJ; Bailey JE; Nutt DJ. (Jun 2005). Dizziness produced by a potent 5HT(1A) receptor agonist (eptapirone) is not due to postural hypotension. Psychopharmacology (Berl). 179:895-896. DOI.
• Nutt DJ. (May 2005). Making sense of GABA(A) receptor subtypes: is a new nomenclature needed?. J Psychopharmacol. 19:219-220. DOI.
• Wilson S; Nutt D. (Mar 2005). Assessment and management of insomnia. Clin Med. 5:101-104.
• Nutt DJ. (Mar 2005). Death by tricyclic: the real antidepressant scandal?. J Psychopharmacol. 19:123-124. DOI.
• Gonzalez A; Nutt DJ. (Mar 2005). Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol. 19:195-204.
• Nutt DJ. (Mar 2005). NICE: The National Institute of Clinical Excellence -- or Eccentricity? Reflections on the Z-drugs as hypnotics. J Psychopharmacol. 19:125-127. DOI.
• Tyacke RJ; Robinson ESJ; Lalies MDM; Hume SP; Hudson AL; Nutt DJ. (Feb 2005). Estimation of endogenous noradrenaline release in rat brain in vivo using [H-3]RX 821002. SYNAPSE. 55:126-132. DOI.
• Fone KC; Nutt DJ. (Feb 2005). Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 5:87-93. DOI.
• Saczewski F; Kobierska E; Tyacke RJ; Hudson AL; Nutt DJ; Gdaniec M. (Feb 2005). Synthesis of 2,3,5,6-tetrahydro-3H-imidazo[2,1-b] [1,3,5]benzotriazepines and their oxidative ring contraction into 1-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzimidazoles. Farmaco. 60:127-134. DOI.
• Bailey JE; Argyropoulos SV; Kendrick AH; Nutt DJ. (2005). Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety. 21:18-25. DOI.
• Nutt D. (Jan 2005). Cannabis antagonists: a new era of social psychopharmacology?. J Psychopharmacol. 19:3-4. DOI.
• Nutt DJ. (1 Jan 2005). Discontinuation of Vioxx. Lancet. 365:28. DOI.
• Daglish M; Lingford-Hughes A; Nutt D. (2005). Human functional neuroimaging connectivity research in dependence. Rev Neurosci. 16:151-157.
• Nutt DJ. (Jan 2005). Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10:49-56.
• Nash JR; Nutt DJ. (2005). Pharmacotherapy of anxiety. Handb Exp Pharmacol. 469-501.
• Kornicka A; Saczewski F; Petrusewicz J; Rejdych A; Tyacke RJ; Hudson AL; Nutt DJ. (Jan 2005). Synthesis and biological activities of novel 1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline derivatives. POL J CHEM. 79:89-100.
• Melichar JK; Hume SP; Williams TM; Daglish MRC; Taylor LG; Ahmad R; Malizia AL; Brooks DJ; et alMyles JS; Lingford-Hughes A; Nutt DJ. (Jan 2005). Using [C-11]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: Clinical and preclinical studies. J PHARMACOL EXP THER. 312:309-315. DOI.
• Parker CA; Anderson NJ; Robinson ES; Price R; Tyacke RJ; Husbands SM; Dillon MP; Eglen RM; et alHudson AL; Nutt DJ; Crump MP; Crosby J. (28 Dec 2004). Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry. 43:16385-16392. DOI.
• Argyropoulos SV; Hood SD; Adrover M; Bell CJ; Rich AS; Nash JR; Rich NC; Witchel HJ; et alNutt DJ. (1 Oct 2004). Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry. 56:503-509. DOI.
• Wilson SJ; Bailey JE; Rich AS; Adrover M; Potokar J; Nutt DJ. (Oct 2004). Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur Neuropsychopharmacol. 14:367-372. DOI.
• Lingford-Hughes AR; Welch S; Nutt DJ; British Association for Psychopharmacology. (Sep 2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 18:293-335. DOI.
• Walling SG; Nutt DJ; Lalies MD; Harley CW. (25 Aug 2004). Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. J Neurosci. 24:7421-7426. DOI.
• Nutt D; Lingford-Hughes A. (3 Aug 2004). Infecting the brain to stop addiction?. Proc Natl Acad Sci U S A. 101:11193-11194. DOI.
• Kaluev AV; Nutt DJ. (Jul 2004). [On the role of GABA in anxiety and depression]. Eksp Klin Farmakol. 67:71-76.
• Robinson ES; Tyacke RJ; Finch L; Willmott G; Husbands S; Nutt DJ; Hudson AL. (May 2004). Pharmacological characterisation of novel alpha 2-adrenoceptor antagonists as potential brain imaging agents. Neuropharmacology. 46:847-855. DOI.
• Davies SJ; Jackson PR; Potokar J; Nutt DJ. (17 Apr 2004). Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ. 328:939-943. DOI.
• Pyle AC; Argyropoulos SV; Nutt DJ. (Apr 2004). The role of serotonin in panic: evidence from tryptophan depletion studies. ACTA NEUROPSYCHIATR. 16:79-84.
• Kaye J; Buchanan F; Kendrick A; Johnson P; Lowry C; Bailey J; Nutt D; Lightman S. (Mar 2004). Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. J Neuroendocrinol. 16:256-264. DOI.
• Wilson SJ; Rich AS; Rich NC; Potokar J; Nutt DJ. (Mar 2004). Evaluation of actigraphy and automated telephoned questionnaires to assess hypnotic effects in insomnia. Int Clin Psychopharmacol. 19:77-84.
• Finn DP; Hudson AL; Kinoshita H; Coventry TL; Jessop DS; Nutt DJ; Harbuz MS. (Mar 2004). Imidazoline2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic-pituitary-adrenal axis activity in control and acute restraint stressed rats. J Psychopharmacol. 18:47-53. DOI.
• Slattery DA; Hudson AL; Nutt DJ. (Feb 2004). Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol. 18:1-21.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Marshall RD; Nemeroff CB; Shalev AY; Yehuda R. (2004). Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 65 Suppl 1:55-62.
• Nutt DJ; Malizia AL. (2004). Structural and functional brain changes in posttraumatic stress disorder. J Clin Psychiatry. 65 Suppl 1:11-17.
• Ballenger JC; Davidson JRT; Lecrubier Y; Nutt DJ; Int Consensus Grp Depression Anxie. (2004). Update on posttraumatic stress disorder - Introduction. J CLIN PSYCHIAT. 65:3-3.
• Daglish MR; Nutt DJ. (Dec 2003). Brain imaging studies in human addicts. Eur Neuropsychopharmacol. 13:453-458.
• Robinson ES; Price RE; Nutt DJ; Hudson AL. (Dec 2003). BU98008, a highly selective imidazoline(1)-receptor ligand. Ann N Y Acad Sci. 1009:283-287.
• Anderson NJ; Robinson ES; Husbands SM; Delagrange P; Nutt DJ; Hudson AL. (Dec 2003). Characterization of [(3)H]harmane binding to rat whole brain membranes. Ann N Y Acad Sci. 1009:175-179.
• Nutt DJ. (Dec 2003). Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol. 17:355-364.
• Robinson ES; Anderson NJ; Crosby J; Nutt DJ; Hudson AL. (Dec 2003). Endogenous beta-carbolines as clonidine-displacing substances. Ann N Y Acad Sci. 1009:157-166.
• Daglish MRC; Weinstein A; Malizia AL; Wilson S; Melichar JK; Lingford-Hughes A; Myles JS; Grasby P; et alNutt DJ. (Dec 2003). Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"?. NEUROIMAGE. 20:1964-1970. DOI.
• Kimura A; Tyacke RJ; Minchin MC; Nutt DJ; Hudson AL. (Dec 2003). Identification of an I(2) binding protein from rabbit brain. Ann N Y Acad Sci. 1009:364-366.
• Paterson LM; Robinson ES; Nutt DJ; Hudson AL. (Dec 2003). In vivo estimation of imidazoline(2) binding site turnover. Ann N Y Acad Sci. 1009:367-370.
• Tyacke RJ; Sazczewski F; Tabin P; Sazczewski J; Nutt DJ; Hudson AL. (Dec 2003). Initial evaluation of novel selective ligands for imidazoline(2) receptors in rat whole brain. Ann N Y Acad Sci. 1009:357-360.
• Tyacke RJ; Lau A; Grella B; Glennon RA; Nutt DJ; Hudson AL. (Dec 2003). Investigation of the affinities of two new beta-carbolines for rat brain imidazoline(2) receptors. Ann N Y Acad Sci. 1009:361-363.
• Hudson AL; Tyacke RJ; Lalies MD; Davies N; Finn DP; Marti O; Robinson E; Husbands S; et alMinchin MC; Kimura A; Nutt DJ. (Dec 2003). Novel ligands for the investigation of imidazoline receptors and their binding proteins. Ann N Y Acad Sci. 1009:302-308.
• Paterson LM; Tyacke RJ; Nutt DJ; Hudson AL. (Dec 2003). Relationship between imidazoline(2) sites and monoamine oxidase. Ann N Y Acad Sci. 1009:353-356.
• Nash JR; Wilson SJ; Potokar JP; Nutt DJ. (28 Oct 2003). Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology. 61:1161.
• Saczewski F; Hudson AL; Tyacke RJ; Nutt DJ; Man J; Tabin P; Saczewski J. (Oct 2003). 2-(4,5-dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I(2) imidazoline receptor ligands. Eur J Pharm Sci. 20:201-208.
• Argyropoulos SV; Hicks JA; Nash JR; Bell CJ; Rich AS; Nutt DJ; Wilson SJ. (30 Sep 2003). Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res. 120:179-190.
• Smith A; Brice C; Nash J; Rich N; Nutt DJ. (Sep 2003). Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol. 17:283-292.
• Bailey JE; Argyropoulos SV; Lightman SL; Nutt DJ. (Sep 2003). Does the brain noradrenaline network mediate the effects of the CO2 challenge?. J Psychopharmacol. 17:252-259.
• Bailey JE; Argyropoulos SV; Lightman SL; Nutt DJ. (Sep 2003). Does the brain noradrenaline network mediate the effects of the CO2 challenge? Reply to reviewers' comments. J PSYCHOPHARMACOL. 17:267-268.
• Nutt DJ. (Sep 2003). The unhappy saga of 'happy pills'. J Psychopharmacol. 17:251.
• Allgulander C; Bandelow B; Hollander E; Montgomery SA; Nutt DJ; Okasha A; Pollack MH; Stein DJ; et alSwinson RP; World Council of Anxiety. (Aug 2003). WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 8:53-61.
• Greist JH; Bandelow B; Hollander E; Marazziti D; Montgomery SA; Nutt DJ; Okasha A; Swinson RP; et alZohar J; World Council of Anxiety. (Aug 2003). WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 8:7-16.
• Pollack MH; Allgulander C; Bandelow B; Cassano GB; Greist JH; Hollander E; Nutt DJ; Okasha A; et alSwinson RP; World Council of Anxiety. (Aug 2003). WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 8:17-30.
• Stein DJ; Bandelow B; Hollander E; Nutt DJ; Okasha A; Pollack MH; Swinson RP; Zohar J; et alWorld Council of Anxiety. (Aug 2003). WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 8:31-39.
• Van Ameringen M; Allgulander C; Bandelow B; Greist JH; Hollander E; Montgomery SA; Nutt DJ; Okasha A; et alPollack MH; Stein DJ; Swinson RP; World Council of Anxiety. (Aug 2003). WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 8:40-52.
• Weinstein A; Feldtkeller B; Feeney A; Lingford-Hughes A; Nutt D. (Jun 2003). A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addict Biol. 8:229-232. DOI.
• Nutt DJ. (Jun 2003). British Association for Psychopharmacology consensus on the treatment of bipolar disorder. J PSYCHOPHARMACOL. 17:147-147.
• Finn DP; Martí O; Harbuz MS; Vallès A; Belda X; Márquez C; Jessop DS; Lalies MD; et alArmario A; Nutt DJ; Hudson AL. (May 2003). Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl). 167:195-202. DOI.
• Coupland NJ; Wilson SJ; Potokar JP; Bell C; Nutt DJ. (1 May 2003). Increased sympathetic response to standing in panic disorder. Psychiatry Res. 118:69-79.
• Hood SD; Argyropoulos SV; Nutt DJ. (Apr 2003). New directions in the treatment of anxiety disorders. EXPERT OPIN THER PAT. 13:401-423.
• Bell C; Wilson S; Rich A; Bailey J; Nutt D. (Mar 2003). Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology (Berl). 166:102-110. DOI.
• Melichar JK; Myles JS; Eap CB; Nutt DJ. (Mar 2003). Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol. 8:59-66. DOI.
• Law FD; Nutt DJ. (22 Feb 2003). Maintenance buprenorphine for opioid users. Lancet. 361:634-635. DOI.
• Witchel HJ; Hancox JC; Nutt DJ; Wilson S. (Feb 2003). Antipsychotics, HERG and sudden death. Br J Psychiatry. 182:171-172.
• Lingford-Hughes A; Nutt D. (Feb 2003). Neurobiology of addiction and implications for treatment. Br J Psychiatry. 182:97-100.
• Witchel HJ; Hancox JC; Nutt DJ. (Feb 2003). Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 23:58-77.
• Melichar JK; Nutt DJ; Malizia AL. (17 Jan 2003). Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol. 459:217-219.
• Lingford-Hughes AR; Davies SJ; McIver S; Williams TM; Daglish MR; Nutt DJ. (2003). Addiction. Br Med Bull. 65:209-222.
• Nutt D; Lingford-Hughes A; Daglish M. (2003). Future directions in substance dependence research. J Neural Transm Suppl. 95-103.
• Wilson SJ; Bailey JE; Alford C; Weinstein A; Nutt DJ. (Dec 2002). Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol. 16:321-331.
• Nutt DJ; Ballenger JC; Sheehan D; Wittchen HU. (Dec 2002). Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 5:315-325. DOI.
• Nutt DJ; Hewett K; Bryson H; Iyengar M; Oakes R. (Oct 2002). Generalised anxiety disorder: Remission status in patients treated with paroxetine. EUR NEUROPSYCHOPHARM. 12:S345-S346.
• Nutt DJ; Law F. (Oct 2002). The ideal treatment of withdrawal. EUR NEUROPSYCHOPHARM. 12:S121-S123.
• Wilson S; Bailey J; Rich A; Adrover M; Nutt DJ. (Oct 2002). Using sleep to measure relative 5HT uptake blockade. EUR NEUROPSYCHOPHARM. 12:S200-S200.
• Daglish MRC; Lingford-Hughes A; Williams TM; Wilsona SJ; Brooksc DJ; Myles JS; Grasby P; Nutt DJ. (Sep 2002). A human pet study of dopamine response to hydromorphone. BEHAV PHARMACOL. 13:479-480.
• Bell C; Vanderlinden H; Hiersemenzel R; Otoul C; Nutt D; Wilson S. (Sep 2002). The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. J Sleep Res. 11:255-263.
• Hardy J; Argyropoulos S; Nutt DJ. (Sep 2002). Venlafaxine: a new class of antidepressant. Hosp Med. 63:549-552.
• Robinson ES; Tyacke RJ; Nutt DJ; Hudson AL. (16 Aug 2002). Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. Eur J Pharmacol. 450:55-60.
• Argyropoulos SV; Bailey JE; Hood SD; Kendrick AH; Rich AS; Laszlo G; Nash JR; Lightman SL; et alNutt DJ. (Aug 2002). Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology. 27:715-729.
• Lingford-Hughes A; Hume S; Feeney A; Hirani E; Osman S; Cunningham V; Pike V; Brooks D; et alNutt D. (Jul 2002). [11C]Ro15 4513 PET predominantly labels the alpha 5-containing GABA-benzodiazepine receptor in vivo. NEUROIMAGE. 16:S27-S27.
• Tyacke RJ; Robinson ES; Nutt DJ; Hudson AL. (Jul 2002). 5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: in vitro and in vivo characterisation in rat brain. Neuropharmacology. 43:75-83.
• Daglish M; Lingford-Hughes A; Williams T; Wilson S; Brooks D; Myles J; Grasby P; Nutt D. (Jul 2002). Does opioid induced dopamine release in humans require a subjective "high"? A pet study with 11C-raclopride. NEUROIMAGE. 16:S95-S95.
• Lingford-Hughes A; Hume SP; Feeney A; Hirani E; Osman S; Cunningham VJ; Pike VW; Brooks DJ; et alNutt DJ. (Jul 2002). Imaging the GABA-benzodiazepine receptor subtype containing the alpha 5-subunit in vivo with [C-11]Ro15 4513 positron emission tomography. J CEREBR BLOOD F MET. 22:878-889.
• Finn DP; Lalies MD; Harbuz MS; Jessop DS; Hudson AL; Nutt DJ. (Jun 2002). Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. Neuropharmacology. 42:958-965.
• Hicks JA; Argyropoulos SV; Rich AS; Nash JR; Bell CJ; Edwards C; Nutt DJ; Wilson SJ. (Jun 2002). Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry. 180:528-535.
• Nutt DJ. (Jun 2002). The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 17 Suppl 1:S1-12.
• Nutt DJ. (Jun 2002). Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 17 Suppl 1:S37-S41. DOI.
• Wilson SJ; Argyropoulos S; Nash J; Hicks JA; Bel CE; Nutt DJ. (May 2002). Exploring antidepressant mechanisms by acute and chronic sleep effects. EUR PSYCHIAT. 17:72S-72S.
• Tyacke RJ; Robinson ES; Schnabel R; Lewis JW; Husbands SM; Nutt DJ; Hudson AL. (May 2002). N1'-fluoroethyl-naltrindole (BU97001) and N1'-fluoroethyl-(14-formylamino)-naltrindole (BU97018) potential delta-opioid receptor PET ligands. Nucl Med Biol. 29:455-462.
• Nutt DJ. (Apr 2002). Addiction. EUR NEUROPSYCHOPHARM. 12:S29-S29.
• Daglish MRC; Lingford-Hughes A; Williams TM; Davies SJC; Melichar JK; Brooks DJ; Myles JS; Nutt DJ. (Mar 2002). A PET study of brain opioid receptor changes after withdrawal from chronic methadone treatment. EUR NEUROPSYCHOPHARM. 12:S22-S22.
• Daglish MRC; Lingford-Hughes A; Williams T; Wilson S; Brooks DJ; Myles JS; Grasby P; Nutt DJ. (Mar 2002). A PET study testing the dopamine hypothesis in opiate dependence in humans. EUR NEUROPSYCHOPHARM. 12:S22-S23.
• Melichar JK; Taylor LG; Daglish MRC; Holmes RB; Parkin VJ; Rees MR; Lenox-Smith A; Lingford-Hughes AR; et alNutt DJ. (Mar 2002). A single photon emission tomography (SPET) study of noradrenergic function in generalised anxiety disorder (GAD). EUR NEUROPSYCHOPHARM. 12:S20-S21.
• Wilson S; Lingford-Hughes A; Cunningham VJ; Gunn R; Feeney A; Stevenson BJ; Myles J; Brooks DJ; et alNutt DJ. (Mar 2002). Assessing the function of the GABA-benzodiazepine receptor in alcohol dependence using PET and EEG. EUR NEUROPSYCHOPHARM. 12:S21-S21.
• Lingford-Hughes A; Daglish MRC; Wilson S; Weinstein A; Malizia AL; Melichar JK; Stevenson BJ; Feeney A; et alPandit SA; Myles JS; Grasby PJ; Nutt DJ. (Mar 2002). Blood flow changes in abstinent addicts during cue exposure and craving for their drug of choice. EUR NEUROPSYCHOPHARM. 12:S21-S22.
• Bell C; Forshall S; Adrover M; Nash J; Hood S; Argyropoulos S; Rich A; Nutt DJ. (Mar 2002). Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 16:5-14.
• Lingford-Hughes A; Hume SP; Feeney A; Hirani E; Osman S; Cunningham VJ; Pike VW; Brooks DJ; et alNutt DJ. (Mar 2002). Imaging in vivo the GABA-benzodiazepine receptor containing the alpha 5 subunit in man and rat. EUR NEUROPSYCHOPHARM. 12:S20-S20.
• Willmott G; Robinson ESJ; Tyacke RJ; Nutt DJ; Hudson AL. (Feb 2002). Functional characterisation of novel alpha(2)-adrenoceptor ligands in the mouse vas deferens. BRIT J PHARMACOL. 135.
• Finch L; Tyacke RJ; Robinson ESJ; Nutt DJ; Hudson AL. (Feb 2002). In vitro evaluation of three potential SPECT ligands for the central alpha(2)-adrenoceptor. BRIT J PHARMACOL. 135.
• Edwards MM; Jackson HC; Nutt DJ; Hudson AL. (Feb 2002). Investigation of the acute administration of imidazoline ligands on food intake. BRIT J PHARMACOL. 135.
• Allgulander C; Hirschfeld RM; Nutt DJ. (2002). Long-term treatment strategies in anxiety disorders. Psychopharmacol Bull. 36 Suppl 2:79-92.
• Artigas F; Nutt DJ; Shelton R. (2002). Mechanism of action of antidepressants. Psychopharmacol Bull. 36 Suppl 2:123-132.
• Argyropoulos SV; Bell CJ; Nutt DJ. (Dec 2001). Brain function in social anxiety disorder. Psychiatr Clin North Am. 24:707-722.
• Crofts HS; Wilson S; Muggleton NG; Nutt DJ; Scott EA; Pearce PC. (Dec 2001). Investigation of the sleep electrocorticogram of the common marmoset (Callithrix jacchus) using radiotelemetry. Clin Neurophysiol. 112:2265-2273.
• Abrams JK; Bell CJ; Nutt DJ. (Dec 2001). Tryptophan depletion as a clinical tool: Current status and future directions. INT J PSYCHIAT CLIN. 5:237-247.
• Nutt DJ; Malizia AL. (Nov 2001). New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 179:390-396.
• Husbands SM; Glennon RA; Gorgerat S; Gough R; Tyacke R; Crosby J; Nutt DJ; Lewis JW; et alHudson AL. (1 Oct 2001). beta-carboline binding to imidazoline receptors. Drug Alcohol Depend. 64:203-208.
• Daglish MRC; Weinstein A; Malizia AL; Wilson S; Melichar JK; Britten S; Brewer C; Lingford-Hughes A; et alMyles JS; Grasby P; Nutt DJ. (Oct 2001). Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. AM J PSYCHIAT. 158:1680-1686.
• Sandford JJ; Forshall S; Bell C; Argyropoulos S; Rich A; D'Orlando KJ; Gammans RE; Nutt DJ. (Sep 2001). Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 15:205-208.
• Hood SD; Argyropoulos SV; Nutt DJ. (Aug 2001). Arthritis and serotonergic antidepressants. J Clin Psychopharmacol. 21:458-461.
• Feldtkeller B; Weinstein A; Cox WM; Nutt D. (Aug 2001). Effects of contextual priming on reactions to craving and withdrawal stimuli in alcohol-dependent participants. Exp Clin Psychopharmacol. 9:343-351.
• Ballenger JC; Ballenger JC; Davidson JRT; Lecrubier Y; Nutt DJ. (2001). Focus on depression and anxiety disorders in general medicine - Introduction. J CLIN PSYCHIAT. 62:3-3.
• Nutt DJ. (Jul 2001). Panic disorder: Clinical diagnosis, management and mechanism. AM J PSYCHIAT. 158:1176-1177.
• Daglish M; Lingford-Hughes A; Stevenson B; Feeney A; Myles J; Grasby P; Nutt D. (Jun 2001). Mapping neural activation to alcohol cues in abstinent alcoholics - variability of behavioural and rCBF responses in the scanner environment. NEUROIMAGE. 13:S1039-S1039.
• Robinson ESJ; Tyacke RJ; Nutt DJ; Hudson AL. (May 2001). Effect of BU99006, an irreversible imidazolme(2) binding site ligand, in the distribution of [H-3]2BFI and of [H-3]RX82I002 binding to rat brain sections. BRIT J PHARMACOL. 133:U72-U72.
• Tyacke RJ; Paterson LM; Nutt DJ; Hudson AL. (May 2001). Pre-treatment with imidazoline(2) binding site compounds increases the binding of [H-3]2BFI in rat brain membranes. BRIT J PHARMACOL. 133:U72-U72.
• Finn DP; Hudson AL; Harbuz MS; Nutt DJ; Marti O. (May 2001). The effect of the imidazoline(2) (I-2) site selective ligand BU224 in rat exposed to a forced swim test paradigm. BRIT J PHARMACOL. 133:U94-U94.
• Bell C; Abrams J; Nutt D. (May 2001). Tryptophan depletion and its implications for psychiatry. Br J Psychiatry. 178:399-405.
• Clayson J; Jales A; Tyacke RJ; Hudson AL; Nutt DJ; Lewis JW; Husbands SM. (9 Apr 2001). Selective delta-opioid receptor ligands: potential PET ligands based on naltrindole. Bioorg Med Chem Lett. 11:939-943.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ. (Apr 2001). A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care. Prim Care Companion J Clin Psychiatry. 3:44-52.
• Argyropoulos SV; Hood SD; Nutt DJ. (Apr 2001). Social phobia: illness or illusion?. Acta Psychiatr Scand. 103:241-243.
• Coupland NJ; Bell C; Potokar JP; Bailey JE; Nutt DJ. (Mar 2001). Cardiovascular reflexes during treatment of social phobia with moclobemide. INT J PSYCHIAT CLIN. 5:27-31.
• Pandit SA; Argyropoulos S; Nutt DJ. (Mar 2001). Current status of anxiolytic drugs. PRIMARY CARE PSYCHIA. 7:1-5.
• Melichar JK; Daglish MR; Nutt DJ. (Feb 2001). Addiction and withdrawal--current views. Curr Opin Pharmacol. 1:84-90.
• Okada M; Nutt DJ; Murakami T; Zhu G; Kamata A; Kawata Y; Kaneko S. (15 Jan 2001). Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci. 21:628-640.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Roose SP; Sheps DS; International Consensus Group on Depression and Anxiety. (2001). Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry. 62 Suppl 8:24-27.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Lydiard RB; Mayer EA; International Consensus Group on Depression and Anxiety. (2001). Consensus statement on depression, anxiety, and functional gastrointestinal disorders. J Clin Psychiatry. 62 Suppl 8:48-51.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Jones RD; Berard RM; International Consensus Group on Depression and Anxiety. (2001). Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry. 62 Suppl 8:64-67.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Borkovec TD; Rickels K; Stein DJ; Wittchen HU. (2001). Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 62 Suppl 11:53-58.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Kirmayer LJ; Lépine JP; Lin KM; Tajima O; et alOno Y. (2001). Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 62 Suppl 13:47-55.
• Nutt DJ. (2001). Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 62 Suppl 11:22-27.
• Nutt D. (2001). Social phobia. NORD J PSYCHIAT. 55:78-78.
• Melichar JK; Haida A; Rhodes C; Reynolds AH; Nutt DJ; Malizia AL. (2001). Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. J PSYCHOPHARMACOL. 15:9-12.
• Argyropoulos SV; Sandford JJ; Nutt DJ. (Dec 2000). The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety. Pharmacol Ther. 88:213-227.
• Sandford JJ; Argyropoulos SV; Nutt DJ. (Dec 2000). The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology. Pharmacol Ther. 88:197-212.
• Nutt D. (Dec 2000). Treatment of depression and concomitant anxiety. Eur Neuropsychopharmacol. 10 Suppl 4:S433-S437.
• Evans J; Reeves B; Platt H; Leibenau A; Goldman D; Jefferson K; Nutt D. (Nov 2000). Impulsiveness, serotonin genes and repetition of deliberate self-harm (DSH). Psychol Med. 30:1327-1334.
• Weinstein AM; Feldtkeller BT; Law F; Myles J; Nutt DJ. (Nov 2000). The processing of automatic thoughts of drug use and craving in opiate-dependent individuals. Exp Clin Psychopharmacol. 8:549-553.
• Finn DP; Lalies MD; Harbuz MS; Hudson AL; Nutt DJ. (Oct 2000). Effect of the imidazoline(2) (I-2) site-selective ligand BU224 on in vivo noradrenaline release and plasma corticosterone in control and chronically stressed rats. BRIT J PHARMACOL. 131:U17-U17.
• Tyacke RJ; Robinson ESJ; Hudson AL; Nutt DJ. (Oct 2000). In vivo inactivation of imidazoline(2) binding sites by a novel irreversible ligand. BRIT J PHARMACOL. 131:U25-U25.
• Slattery DA; Hudson AL; Nutt DJ. (Oct 2000). Inhibition of imidazoline I-2 site binding by potassium channel modulators. BRIT J PHARMACOL. 131:U26-U26.
• Nutt DJ; Price R; Tyacke R; Husbands S; Lewis J; Finn D; Lalies M; Hudson AL. (Oct 2000). New approaches to imidazoline receptors. EUR PSYCHIAT. 15:280S-280S.
• Argyropoulos SV; Nutt DJ. (Aug 2000). Substance P antagonists: novel agents in the treatment of depression. Expert Opin Investig Drugs. 9:1871-1875. DOI.
• Hood SD; Argyropoulos SV; Nutt DJ. (Jun 2000). Agents in development for anxiety disorders - Current status and future potential. CNS DRUGS. 13:421-431.
• Potokar J; Nash J; Sandford J; Rich A; Nutt D. (Jun 2000). GABAAbenzodiazepine receptor (GBzR) sensitivity: test-retest reliability in normal volunteers. Hum Psychopharmacol. 15:281-286. DOI.
• Nutt DJ. (Jun 2000). New Directions in Anxiety: OCD Spectrum Disorders. CNS SPECTRUMS. 5:32-36.
• Lingford-Hughes A; Nutt D. (May 2000). Alcohol and drug abuse. CURR OPIN PSYCHIATR. 13:291-298.
• Williams K; Argyropoulos S; Nutt DJ. (May 2000). Amphetamine misuse and social phobia. Am J Psychiatry. 157:834-835.
• Robinson ES; Nutt DJ; Jackson HC; Hudson AL. (May 2000). Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat. Br J Pharmacol. 130:153-159. DOI.
• Daglish MR; Melichar JK; Lingford-Hughes AR; Brooks DJ; Myles JS; Nutt DJ. (May 2000). C-11-diprenorphine PET imaging of opioid binding during chronic methadone treatment and early abstinence. J NUCL MED. 41:106P-106P.
• Hume SP; Hirani E; Opacka-Juffry J; Osman S; Myers R; Gunn RN; McCarron JA; Clark RD; et alMelichar J; Nutt DJ; Pike VW. (May 2000). Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors. Eur J Nucl Med. 27:475-484.
• Wilson SJ; Bell C; Coupland NJ; Nutt DJ. (May 2000). Sleep changes during long-term treatment of depression with fluvoxamine--a home-based study. Psychopharmacology (Berl). 149:360-365.
• Lingford-Hughes AR; Cunningham VJ; Feeney AJ; Wilson SJ; Gunn RN; Stephenson B; Brooks DJ; Nutt DJ. (May 2000). The function of the GABA-benzodiazepine receptor in alcohol dependence. J NUCL MED. 41:136P-136P.
• Evans J; Platts H; Lightman S; Nutt D. (Apr 2000). Impulsiveness and the prolactin response to d-fenfluramine. Psychopharmacology (Berl). 149:147-152.
• Coates PA; Grundt P; Robinson ES; Nutt DJ; Tyacke R; Hudson AL; Lewis JW; Husbands SM. (20 Mar 2000). Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 10:605-607.
• Malizia AL; Melichar JK; Rhodes CG; Haida A; Reynolds AH; Jones T; Nutt DJ. (17 Mar 2000). Desipramine binding to noradrenaline reuptake sites in cardiac sympathetic neurons in man in vivo. EUR J PHARMACOL. 391:263-267.
• Potokar JP; Nutt DJ. (Mar 2000). Chest pain: panic attack or heart attack?. Int J Clin Pract. 54:110-114.
• Anderson IM; Nutt DJ; Deakin JFW; Consensus Meeting British Assoc Ps. (Mar 2000). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J PSYCHOPHARMACOL. 14:3-20.
• Anderson IM; Nutt DJ; Deakin JF. (Mar 2000). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 14:3-20.
• Parker CA; Hudson AL; Nutt DJ; Dillon MP; Eglen RM; Crosby J. (3 Jan 2000). Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells. Eur J Pharmacol. 387:27-30.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Foa EB; Kessler RC; McFarlane AC; Shalev AY. (2000). Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 61 Suppl 5:60-66.
• Coupland NJ; Bell C; Potokar JP; Dorkins E; Nutt DJ. (2000). Flumazenil challenge in social phobia. Depress Anxiety. 11:27-30.
• Wilson SJ; Bailey JE; Alford C; Nutt DJ. (2000). Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. J Psychopharmacol. 14:378-386.
• Nutt DJ. (2000). The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 61 Suppl 5:24-29.
• Potokar J; Lawson C; Wilson S; Nutt D. (15 Dec 1999). Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry. 46:1709-1711.
• Hudson AL; Robinson ES; Lalies MD; Tyacke RJ; Jackson HC; Nutt DJ. (Dec 1999). In vitro and in vivo approaches to the characterization of the alpha2-adrenoceptor. J Auton Pharmacol. 19:311-320.
• Nutt DJ. (Dec 1999). The imaging science of PET. J PSYCHOPHARMACOL. 13:323-323.
• Argyropoulos SV; Nutt DJ. (Dec 1999). The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol. 9 Suppl 6:S407-S412.
• Ernst E; Gerada C; Hood S; Nutt D. (Nov 1999). A depressed man requesting St John's wort. Practitioner. 243:779-786.
• Smith A; Clark R; Nutt D; Haller J; Hayward S; Perry K. (Oct 1999). Anti-oxidant vitamins and mental performance of the elderly. HUM PSYCHOPHARM CLIN. 14:459-471.
• Robinson ES; Nutt DJ; Hall L; Jackson HC; Hudson AL. (Oct 1999). Autoradiographical and behavioural effects of a chronic infusion of antisense to the alpha2D-adrenoceptor in the rat. Br J Pharmacol. 128:515-522. DOI.
• Parker CA; Hudson AL; Nutt DJ; Dillon MP; Eglen RM; Crosby J. (Oct 1999). Reverse phase-HPLC analysis of clonidine-displacing substance present in NG108-15 cells. BRIT J PHARMACOL. 128:U102-U102.
• Potokar J; Coupland N; Wilson S; Rich A; Nutt D. (Sep 1999). Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. Psychopharmacology (Berl). 146:180-184.
• Nutt D; Law J. (Sep 1999). Treatment of cluster headache with mirtazapine. Headache. 39:586-587.
• Parker CA; Hudson AL; Nutt DJ; Dillon MP; Eglen RM; Chan SL; Morgan NG; Crosby J. (6 Aug 1999). Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues. Eur J Pharmacol. 378:213-221.
• Nutt D. (Aug 1999). Alcohol and the brain. Pharmacological insights for psychiatrists. Br J Psychiatry. 175:114-119.
• Crofts HS; Muggleton NG; Bowditch AP; Pearce PC; Nutt DJ; Scott EA. (Jul 1999). Home cage presentation of complex discrimination tasks to marmosets and rhesus monkeys. Lab Anim. 33:207-214.
• Nutt DJ; Forshall S; Bell C; Rich A; Sandford J; Nash J; Argyropoulos S. (Jul 1999). Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 9 Suppl 3:S81-S86.
• Tyacke RJ; Nutt DJ; Hudson AL. (21 Jun 1999). Autoradiography of I2 receptors in frog brain. Ann N Y Acad Sci. 881:208-211.
• Parker CA; Hudson AL; Nutt DJ; Dillon MP; Eglen RM; Crosby J. (21 Jun 1999). Comparison of crude methanolic CDS extracts from various tissues. Ann N Y Acad Sci. 881:92-96.
• Hudson AL; Luscombe S; Gouch RE; Nutt DJ; Tyacke RJ. (21 Jun 1999). Endogenous indoleamines demonstrate moderate affinity for I2 binding sites. Ann N Y Acad Sci. 881:212-216.
• Lalies MD; Hibell A; Hudson AL; Nutt DJ. (21 Jun 1999). Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands. Ann N Y Acad Sci. 881:114-117.
• Hudson AL; Gough R; Tyacke R; Lione L; Lalies M; Lewis J; Husbands S; Knight P; et alMurray F; Hutson P; Nutt DJ. (21 Jun 1999). Novel selective compounds for the investigation of imidazoline receptors. Ann N Y Acad Sci. 881:81-91.
• Price RE; Luscombe S; Tyacke RJ; Nutt DJ; Hudson AL. (Jun 1999). Affinities of beta-carbolines for I-2-binding sites in rabbit brain membranes. BRIT J PHARMACOL. 127:U34-U34.
• Edwards MM; Jackson HC; Nutt DJ; Hudson AL. (Jun 1999). Investigation of the affinity of monoamine reuptake inhibitors for rat brain imidazoline 2 binding sites. BRIT J PHARMACOL. 127:U33-U33.
• Finn DP; Harbuz MS; Nutt DJ; Hudson AL. (Jun 1999). The effect of idazoxan on corticosterone levels in control and restraint-stressed rats. BRIT J PHARMACOL. 127:U51-U51.
• Parker CA; Hudson AL; Nutt DJ; Dillon MP; Eglen RM; Crosby J. (Jun 1999). Tryptophan: A distinct but biologically inactive component of clonidine-displacing substance. BRIT J PHARMACOL. 127:U41-U41.
• Lalies MD; Wilson J; Robinson ESJ; Nutt DJ; Hudson AL. (Jun 1999). Unilateral quinolinic acid lesion decreases imidazoline-2 site binding in rat striatum. BRIT J PHARMACOL. 127:U34-U34.
• Robinson ESJ; Nutt DJ; Jackson HC; Hudson AL. (Jun 1999). Uptake of fluorescently labelled antisense to alpha 2(A/D)-adrenoceptors into rat brain following i.c.v. injection. BRIT J PHARMACOL. 127:U33-U33.
• Bell C; Nutt D. (May 1999). Paroxetine and its uses in psychiatry. Hosp Med. 60:353-356.
• Parker CA; Nutt DJ; Hudson AL. (Mar 1999). Autoradiographic study of [H-3]mivazerol binding sites in the rat heart following chemical sympathectomy. BRIT J PHARMACOL. 126:U58-U58.
• Hudson AL; Price R; Tyacke RJ; Lalies MD; Parker CA; Nutt DJ. (Mar 1999). Harmane, norharmane and tetrahydro beta-carboline have high affinity for rat imidazoline binding sites. BRIT J PHARMACOL. 126:U6-U6.
• Finn DP; Harbuz MS; Nutt DJ; Hudson AL. (Mar 1999). The imidazoline(2) (I-2) site-selective ligand BU224 elevates plasma corticosterone in rats. BRIT J PHARMACOL. 126:U72-U72.
• Nutt D. (Mar 1999). Traumatic brain injury and post-traumatic stress disorder - Author's reply. BRIT J PSYCHIAT. 174:275-275.
• Nutt DJ. (1999). Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 60 Suppl 17:23-27.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Goldberg D; Magruder KM; Schulberg HC; Tylee A; et alWittchen HU. (1999). Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 60 Suppl 7:54-61.
• Smith A; Rich N; Sturgess W; Brice C; Collison C; Bailey J; Wilson S; Nutt D. (1999). Effects of the common cold on subjective alertness, reaction time, and eye movements. J PSYCHOPHYSIOL. 13:145-151.
• Chevalier H; Los F; Boichut D; Bianchi M; Nutt DJ; Hajak G; Hetta J; Hoffmann G; et alCrowe C. (1999). Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol. 13:S21-S24.
• Nutt DJ; Wilson S. (1999). Evaluation of severe insomnia in the general population--implications for the management of insomnia: the UK perspective. J Psychopharmacol. 13:S33-S34.
• Nutt DJ; Doble A. (1999). Guest Editorial: Ten years of progress in understanding insomnia, 1988 to 1998. J PSYCHOPHARMACOL. 13:S3-S4.
• Smith A; Sturgess W; Rich N; Brice C; Collison C; Bailey J; Wilson S; Nutt DJ. (1999). The effects of idazoxan on reaction times, eye movements and the mood of healthy volunteers and patients with upper respiratory tract illnesses. J Psychopharmacol. 13:148-151.
• Bell CJ; Malizia AL; Nutt DJ. (1999). The neurobiology of social phobia. Eur Arch Psychiatry Clin Neurosci. 249 Suppl 1:S11-S18.
• Parker CA; Nutt DJ; Hudson AL. (Dec 1998). [H-3]clonidine binding sites in rat kidney: A model for putative central imidazoline-1 sites. BRIT J PHARMACOL. 125:U39-U39.
• Robinson ESJ; Nutt DJ; Jackson HC; Hudson AL. (Dec 1998). Time course of spontaneous behavioural effects of antisense oligonucleotides targeting the alpha(2D)-adrenoceptor in the rat. BRIT J PHARMACOL. 125:U36-U36.
• Nutt D. (21 Nov 1998). Substance-P antagonists: a new treatment for depression?. Lancet. 352:1644-1646. DOI.
• Dalley JW; Parker CA; Wülfert E; Hudson AL; Nutt DJ. (Oct 1998). Potentiation of barbiturate-induced alterations in presynaptic noradrenergic function in rat frontal cortex by imidazol(in)e alpha2-adrenoceptor agonists. Br J Pharmacol. 125:441-446. DOI.
• Eglen RM; Hudson AL; Kendall DA; Nutt DJ; Morgan NG; Wilson VG; Dillon MP. (Sep 1998). 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci. 19:381-390.
• Brice CF; Rich N; Smith A; Nutt D. (Sep 1998). The effects of caffeine and clonidine on eye movements. INT J PSYCHOPHYSIOL. 30:224-224.
• Malizia AL; Cunningham VJ; Bell CJ; Liddle PF; Jones T; Nutt DJ. (Aug 1998). Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 55:715-720.
• O'Brien M; Nutt D. (Aug 1998). Loss of consciousness and post-traumatic stress disorder. A clue to aetiology and treatment. Br J Psychiatry. 173:102-104.
• Nutt D. (Aug 1998). National Institute of Drug Abuse Research Monograph Series: Assessing neurotoxicity of drugs of abuse. ADDICTION. 93:1270-1271.
• Lione LA; Nutt DJ; Hudson AL. (17 Jul 1998). Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. Eur J Pharmacol. 353:123-135.
• Bell CJ; Nutt DJ. (Jun 1998). Serotonin and panic. Br J Psychiatry. 172:465-471.
• Coupland NJ; Melichar J; Bailey JE; Wilson SJ; Nutt DJ. (15 Apr 1998). Effects of alpha(2)-adrenoceptor agonists and antagonists on saccades. BIOL PSYCHIAT. 43:44S-45S.
• Carpene C; Hudson D; Marti L; Remaury A; Morin N; Prevot D; Lalies M; Nutt D; et alLafontan M. (1998). Effects of imidazoline I2-ligands on monoamine oxidase in liver and adipocytes: Acute treatment inhibits activity but chronic treatment does not reduce monoamine oxidase expression. N-S ARCH PHARMACOL. 358:R555-R555.
• Carpene C; Hudson D; Marti L; Remaury A; Morin N; Prevot D; Lalies M; Nutt D; et alLafontan M. (1998). Effects of imidazoline I2-ligands on monoamine oxidase in liver and adipocytes: Acute treatment inhibits activity but chronic treatment does not reduce monoamine oxidase expression. N-S ARCH PHARMACOL. 358:R556-R556.
• Nutt DJ. (1998). Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry. 59 Suppl 8:24-28.
• Hudson A; Gough R; Nutt D. (1998). Autoradiography of imidazoline-2 binding sites in marmoset forebrain. N-S ARCH PHARMACOL. 358:R54-R54.
• Nutt DJ; Bell CJ; Malizia AL. (1998). Brain mechanisms of social anxiety disorder. J Clin Psychiatry. 59 Suppl 17:4-11.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Baldwin DS; den Boer JA; Kasper S; Shear MK. (1998). Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 59 Suppl 8:47-54.
• Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Bobes J; Beidel DC; Ono Y; Westenberg HG. (1998). Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 59 Suppl 17:54-60.
• Nutt DJ. (1998). Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depress Anxiety. 7 Suppl 1:7-10.
• Weinstein A; Feldtkeller B; Malizia A; Wilson S; Bailey J; Nutt DJ. (1998). Integrating the cognitive and physiological aspects of craving. J Psychopharmacol. 12:31-38.
• Bell C; Wilson S; Nutt DJ. (1998). Pindolol augmentation of sertraline in resistant depression and its effect on sleep. J Psychopharmacol. 12:105-107.
• Nutt D; Johnson FN. (1998). Potential applications of venlafaxine. REV CONTEMP PHARMACO. 9:321-331.
• Thomas DN; Nutt DJ; Holman RB. (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J Psychopharmacol. 12:366-370.
• Lione LA; King PD; Nutt DJ; Hunter AJ; Hudson AL. (Dec 1997). An autoradiographic study of alpha(2)-adrenoceptors and imidazoline-2 (I-2) receptors in a rat model of permanent middle cerebral artery occlusion. BRIT J PHARMACOL. 122:U141-U141.
• Argyropoulos SV; Nutt DJ. (Dec 1997). Anhedonia and chronic mild stress model in depression. Psychopharmacology (Berl). 134:333-336.
• Weinstein A; Wilson S; Bailey J; Myles J; Nutt D. (25 Oct 1997). Imagery of craving in opiate addicts undergoing detoxification. Drug Alcohol Depend. 48:25-31.
• Tyacke RJ; Nutt DJ; Chan SLF; Ramsden CA; Morgan NG; Hudson AL. (Oct 1997). Affinities of efaroxan derivatives for alpha(2)-adrenoceptors and I-2-binding sites in rat brain membranes. BRIT J PHARMACOL. 122:P66-P66.
• Lione LA; Nutt DJ; Hudson AL. (Oct 1997). Autoradiographical localisation of imidazoline I-2 sites labelled with [H-3]2-(2-benzofuranyl)-2-imidazoline in rabbit brain. BRIT J PHARMACOL. 122:P65-P65.
• Parker CA; Hudson AL; Nutt DJ. (Oct 1997). Autoradiography of [H-3]mivazerol binding in the rat heart. BRIT J PHARMACOL. 122:P68-P68.
• Lalies MD; Nutt DJ; Hudson AL. (Oct 1997). Chronic clorgyline and deprenyl treatment decrease imidazoline(2) site density in rat interpeduncular nucleus. BRIT J PHARMACOL. 122:P67-P67.
• Hudson AL; Lalies MD; Lione LA; Tyacke RJ; Lewis JW; Nutt DJ. (Oct 1997). New ligands for studying imidazoline receptors. BRIT J PHARMACOL. 122:P180-P180.
• Potokar J; Coupland N; Glue P; Groves S; Malizia A; Bailey J; Wilson S; Nutt D. (Sep 1997). Flumazenil in alcohol withdrawal: a double-blind placebo-controlled study. Alcohol Alcohol. 32:605-611.
• Nutt DJ. (Aug 1997). '''Tis a wonder it works at all!''. ADDICTION. 92:958-959.
• Wilson SJ; Lillywhite AR; Potokar JP; Bell CJ; Nutt DJ. (19 Jul 1997). Adult night terrors and paroxetine. Lancet. 350:185.
• Coupland NJ; Lillywhite A; Bell CE; Potokar JP; Nutt DJ. (1 May 1997). A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. Biol Psychiatry. 41:988-990. DOI.
• Coupland NJ; Bailey JE; Potokar JP; Nutt DJ. (Apr 1997). 5-HT3 receptors, nausea, and serotonin reuptake inhibition. J Clin Psychopharmacol. 17:142-143.
• Evans J; Battersby S; Ogilvie AD; Smith CA; Harmar AJ; Nutt DJ; Goodwin GM. (Apr 1997). Association of short alleles of a VNTR of the serotonin transporter gene with anxiety symptoms in patients presenting after deliberate self harm. Neuropharmacology. 36:439-443.
• Burrows G; Evans L; Baumhackl U; Hebenstreit H; Katschnig H; Schony W; Scholz H; Wilmotte J; et alCampos J; Costa D; Nardi A; Versiani M; daSilva A; Bowen R; Bradwejn J; Johnston D; Plamondon J; Stein M; Swinson R; Chneiweiss L; Bellaire W; Osterheider M; Sonntag R; Cookson J; Freeman C; Hirsch S; Mullin J; Murray R; Nutt D; Petursson H; ODonoghue F; Min J; Allgulander C; Andersch S; Backa H; Realini R; Siegel JL; Buller R; Katschnig H; Stein MB; Buller R. (Apr 1997). Moclobemide in social phobia - A double-blind, placebo-controlled clinical study. EUR ARCH PSY CLIN N. 247:71-80.
• Law FD; Bailey JE; Allen DS; Melichar JK; Myles JS; Mitcheson MC; Lewis JW; Nutt DJ. (Apr 1997). The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. ADDICT BIOL. 2:191-200.
• Robinson ESJ; Nutt DJ; Jackson HC; Hudson AL. (Mar 1997). alpha(2)-Adrenoceptor binding in rat brain following chronic infusion of a phosphorothioate antisense oligonucleotide to the alpha(2D) subtype. BRIT J PHARMACOL. 120:P288-P288.
• Tyacke RJ; Norton CL; Lewis JW; Nutt DJ; Hudson AL. (Mar 1997). Identification of new ligands selective for delta-opioid receptors in guinea-pig brain. BRIT J PHARMACOL. 120:P225-P225.
• Friston KJ; Malizia AL; Wilson S; Cunningham VJ; Jones T; Nutt DJ. (Jan 1997). Analysis of dynamic radioligand displacement or ''activation'' studies. J CEREBR BLOOD F MET. 17:80-93.
• Coupland N; Wilson S; Nutt D. (1997). Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol. 11:83-92.
• Robinson ES; Nutt DJ; Jackson HC; Hudson AL. (1997). Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls. J Psychopharmacol. 11:259-269.
• George DT; Benkelfat C; Rawlings RR; Eckardt MJ; Phillips MJ; Nutt DJ; Wynne D; Murphy DL; et alLinnoila M. (Jan 1997). Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. Am J Psychiatry. 154:81-87.
• Malizia AL; Melichar JM; Brown DJ; Gunn RN; Reynolds A; Jones T; Nutt DJ. (1997). Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 11:279-281.
• Nutt DJ. (1997). Editorial: Psychopharmacology of the prefrontal cortex. J PSYCHOPHARMACOL. 11:98-98.
• Hudson AL; Chapleo CB; Lewis JW; Husbands S; Grivas K; Mallard NJ; Nutt DJ. (Jan 1997). Identification of ligands selective for central I2-imidazoline binding sites. Neurochem Int. 30:47-53.
• Nutt D. (1997). Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry. 58 Suppl 8:11-16.
• Nutt D. (1997). Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl. 391:31-37.
• Nutt DJ. (1997). Noradrenaline in depression: half a century of progress. J Psychopharmacol. 11:S3.
• Nutt DJ; Lalies MD; Lione LA; Hudson AL. (1997). Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol. 11:163-168.
• Melichar JK; Malizia AL; Nutt DJ. (1997). Organization of opioid receptors in human brain and drug interactions studied by PET and SPECT imaging: Implications for treatment strategies for opiate addiction. SEMIN NEUROSCI. 9:131-139.
• Nutt D. (Jan 1997). Psychopharmacology: An introduction, 3rd edition - Spiegel,R. BRIT J PSYCHIAT. 170:96-96.
• Hume SP; Ashworth S; Lammertsma AA; Opacka-Juffry J; Law MP; McCarron JA; Clark RD; Nutt DJ; et alPike VW. (12 Dec 1996). Evaluation in rat of RS-79948-197 as a potential PET ligand for central alpha 2-adrenoceptors. Eur J Pharmacol. 317:67-73.
• Dalley FA; Parker CA; Hudson AL; Nutt DJ. (Oct 1996). Synergistic suppression of extracellular noradrenaline content in the rat forebrain by sodium pentobarbitone and alpha(2)-adrenoceptor agonists. BRIT J PHARMACOL. 119:P38-P38.
• Lione LA; Hudson AL; Nutt DJ; Rogers DC; Davey PT; Hunter AJ. (Oct 1996). The effects of tacrine and the imidazoline 2 site ligand BU224 in the rat delayed T maze. BRIT J PHARMACOL. 119:P205-P205.
• Hudson AL; Bundey R; Nutt DJ; Tyacke RJ. (Oct 1996). The identification of putative imidazoline(2) binding sites in frog brain. BRIT J PHARMACOL. 119:P39-P39.
• Altman J; Everitt BJ; Glautier S; Markou A; Nutt D; Oretti R; Phillips GD; Robbins TW. (Jun 1996). The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology (Berl). 125:285-345.
• Lione LA; Nutt DJ; Hudson AL. (23 May 1996). [3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. Eur J Pharmacol. 304:221-229.
• Reynolds GP; Boulton RM; Pearson SJ; Hudson AL; Nutt DJ. (22 Apr 1996). Imidazoline binding sites in Huntington's and Parkinson's disease putamen. Eur J Pharmacol. 301:R19-R21.
• Lione LA; Nutt DJ; Hudson AL. (Apr 1996). Affinity and selectivity of BU224 and BU239 for rat and guinea-pig brain I-2 imidazoline sites. BRIT J PHARMACOL. 117:P297-P297.
• Lalies MD; Husband C; Dalley JW; Nutt DJ; Hudson AL. (Apr 1996). An investigation of the effect of imidazoline(2)-site selective compounds 2-BFI and BU224 on [H-3]noradrenaline uptake in rat brain slices. BRIT J PHARMACOL. 117:P341-P341.
• Mirza NR; Jackson HC; Dickinson SL; Nutt DJ. (Apr 1996). Effect of the I-2-ligand 2-BFI on passive avoidance performance in the rat. BRIT J PHARMACOL. 117:P177-P177.
• Smith A; Nutt D. (28 Mar 1996). Noradrenaline and attention lapses. Nature. 380:291. DOI.
• Coupland N; Malizia A; Bailey J; Nutt D. (15 Mar 1996). Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK?. Biol Psychiatry. 39:465-466.
• Nutt DJ; Pinder RM. (1996). alpha(2)-Adrenoceptors and depression. J PSYCHOPHARMACOL. 10:35-42.
• Coupland NJ; Wilson SJ; Nutt DJ. (1996). alpha(2)-Adrenoceptors in panic and anxiety disorders. J PSYCHOPHARMACOL. 10:26-34.
• Montgomery SA; Bakish D; Buller R; Gjerris A; Katschnig H; Lecrubier Y; Lepine JP; Mauri M; et alSartorius N; Cameron A; Cassano G; Costa e Silva J; den Boer JA; Freeman C; von Knorring L; Loo H; Nutt D; Rosenberg R. (Mar 1996). ECNP position paper on social phobia proceedings from an ECNP workshop in Jerusalem, October 1994. Eur Neuropsychopharmacol. 6:77-83.
• Tolchard S; Hare AS; Nutt DJ; Clarke G. (Mar 1996). TNF alpha mimics the endocrine but not the thermoregulatory responses of bacterial lipopolysaccharide (LPS): correlation with FOS-expression in the brain. Neuropharmacology. 35:243-248.
• Harley CW; Lalies MD; Nutt DJ. (26 Feb 1996). Estimating the synaptic concentration of norepinephrine in dentate gyrus which produces beta-receptor mediated long-lasting potentiation in vivo using microdialysis and intracerebroventricular norepinephrine. Brain Res. 710:293-298.
• Nutt DJ. (21 Feb 1996). The psychopharmacology of anxiety. Br J Hosp Med. 55:187-191.
• Nutt DJ. (6 Jan 1996). Addiction: brain mechanisms and their treatment implications. Lancet. 347:31-36.
• Malizia AL; Gunn RN; Wilson SJ; Waters SH; Bloomfield PM; Cunningham VJ; Nutt DJ. (1996). Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: Direct measurement of drug occupancy and effects on the human brain in vivo. NEUROPHARMACOLOGY. 35:1483-1491.
• Weinstein AM; Neal L; Lillywhite A; Potokar J; Nutt DJ. (1996). Cognitive processing in post-traumatic stress disorder. Anxiety. 2:130-139. DOI.
• Jordan S; Jackson HC; Nutt DJ; Handley SL. (1996). Discriminative stimulus produced by the imidazoline I-2 site ligand, 2-BFI. J PSYCHOPHARMACOL. 10:273-278.
• Nutt D. (1996). Early action of nefazodone in anxiety associated with depression. J PSYCHOPHARMACOL. 10:18-21.
• Potokar J; Nutt D. (Jan 1996). Psychopharmacology. CURR OPIN PSYCHIATR. 9:98-104.
• Nutt DJ. (1996). Psychopharmacology of social communication. J PSYCHOPHARMACOL. 10:1-1.
• Kalueff A; Nutt DJ. (1996). Role of GABA in memory and anxiety. Depress Anxiety. 4:100-110. DOI.
• Weinstein A; Wilson S; Bailey J; Nutt D. (1996). Sedative antidepressants impair visual detection mechanisms in humans. J PSYCHOPHARMACOL. 10:141-145.
• SITHERS AJ; NUTT DJ; HUDSON AL. (Dec 1995). BINDING OF THE NOVEL ALPHA(2)-ADRENOCEPTOR AGONIST [H-3] MIVAZEROL - COMPARISON WITH [H-3] CLONIDINE. BRIT J PHARMACOL. 116:P439-P439.
• BAINES IA; BOWEN WP; DAYANANDAN R; HUDSON AL; NUTT DJ; MEDHURST AD; HUNTER AJ. (Dec 1995). BU-224 AND 2-BFI HAVE HIGH-AFFINITY FOR 2 DIFFERENT IMIDAZOLINE SITES (I-SITES) IN THE RABBIT. BRIT J PHARMACOL. 116:P374-P374.
• MEDHURST AD; BAINES IA; BOWEN WP; HUDSON AL; NUTT DJ; HUNTER AJ. (Dec 1995). BU-224, 2-BFI, CIRAZOLINE AND IDAZOXAN SHOW SPECIES-DIFFERENCES FOR PUTATNE IMIDAZOLINE SITES (I-SITES) IN KIDNEY CORTEX. BRIT J PHARMACOL. 116:P373-P373.
• LIONE LA; NUTT DJ; HUDSON AL. (Dec 1995). CHARACTERIZATION AND AUTORADIOGRAPHICAL LOCALIZATION OF IMIDAZOLINE-2 (I-2) SITES LABELED BY [(3)H]2-(-2-BENZOFURANYL)-2-IMIDAZOLINE IN RAT-BRAIN. BRIT J PHARMACOL. 116:P338-P338.
• Coupland NJ; Wilson SJ; Potokar JP; Bell CE; Bailey JE; Nutt DJ. (Nov 1995). A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. Int Clin Psychopharmacol. 10:229-238.
• TOLCHARD S; HARE AS; NUTT D; CLARKE G. (Nov 1995). THE INVOLVEMENT OF MEDULLARY CATECHOLAMINERGIC NEURONS IN THE INTERACTION OF THE IMMUNE AND CENTRAL NERVOUS SYSTEMS. J PHYSIOL-LONDON. 489P:P176-P177.
• DALLEY JW; TOLCHARD S; LALIES MD; NUTT DJ. (Oct 1995). ACTIVATION OF RAT LOCUS-COERULEUS NEURONS BY HALOTHANE - A REGIONAL EVALUATION OF TERMINAL NORADRENALINE OVERFLOW AND FOS PROTEIN IMMUNOREACTIVITY. BRIT J PHARMACOL. 116:P100-P100.
• LIONE LA; HUDSON AL; NUTT DJ; ROGERS DC; HUNTER AJ. (Oct 1995). BU224, A HIGH-AFFINITY SELECTIVE I-2 IMIDAZOLINE SITE LIGAND - A BEHAVIORAL-STUDY IN MODELS OF SPATIAL-LEARNING AND MEMORY. BRIT J PHARMACOL. 116:P133-P133.
• Coupland NJ; Bailey JE; Glue P; Nutt DJ. (Sep 1995). The cardiovascular and subjective effects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethyl proline-TRH, in healthy volunteers. Br J Clin Pharmacol. 40:223-229.
• COUPLAND N; NUTT D. (Aug 1995). SUCCESSFUL TREATMENT OF TARDIVE OCULOGYRIC SPASMS WITH VITAMIN-E. J CLIN PSYCHOPHARM. 15:285-286.
• Nutt DJ; French N; Handley S; Hudson A; Husbands S; Jackson H; Jordan S; Lalies MD; et alLewis J; Lione L. (12 Jul 1995). Functional studies of specific imidazoline-2 receptor ligands. Ann N Y Acad Sci. 763:125-139.
• JACKSON HC; GRIFFIN IJ; NUTT DJ. (Jul 1995). EFFECTS OF IMIDAZOLINE(2) (I-2) SITE LIGANDS ON FOOD AND WATER-INTAKE IN THE RAT. BRIT J PHARMACOL. 115:P90-P90.
• MALIZIA AL; NUTT DJ. (Jul 1995). PSYCHOPHARMACOLOGY OF BENZODIAZEPINES - AN UPDATE. HUM PSYCHOPHARM CLIN. 10:S1-S14.
• French N; Lalies MD; Nutt DJ; Pratt JA. (Jun 1995). Idazoxan-induced reductions in cortical glucose use are accompanied by an increase in noradrenaline release: complementary [14C]2-deoxyglucose and microdialysis studies. Neuropharmacology. 34:605-613.
• Coupland NJ; Bailey JE; Wilson SJ; Horvath R; Nutt D. (Jun 1995). The effects of clonidine on cardiovascular responses to standing in healthy volunteers. Clin Auton Res. 5:171-177.
• Malizia AL; Nutt DJ. (Jun 1995). The effects of flumazenil in neuropsychiatric disorders. Clin Neuropharmacol. 18:215-232.
• George DT; Lindquist T; Nutt DJ; Ragan PW; Alim T; McFarlane V; Leviss J; Eckardt MJ; et alLinnoila M. (May 1995). Effect of chloride or glucose on the incidence of lactate-induced panic attacks. Am J Psychiatry. 152:692-697.
• LIONE LA; NUTT DJ; LEWIS J; HUNTER J; TOWERS P; HUDSON AL. (Apr 1995). [H-3] 2-(-2-BENZO-FURANYL)-2-IMIDAZOLINE - A NEW RADIOLIGAND FOR THE STUDY OF RABBIT BRAIN NON-ADRENOCEPTOR IDAZOXAN BINDING-SITES (I2-SITES). BRIT J PHARMACOL. 114:P412-P412.
• FRENCH N; NUTT DJ; PRATT JA. (Apr 1995). 2-(2-BENZO-FURANYL)-2-IMIDAZOLINE-INDUCED ALTERATIONS IN LOCAL CEREBRAL GLUCOSE-UTILIZATION. BRIT J PHARMACOL. 114:P408-P408.
• HUDSON AL; MALLARD NJ; NUTT DJ; CHAPLEO CB. (Apr 1995). AFFINITY AND SELECTIVITY OF 2-(-2-BENZO-FURANYL)-2-IMIDAZOLINE FOR MAMMALIAN BRAIN NON-ADRENOCEPTOR IDAZOXAN BINDING-SITES (I2-SITES). BRIT J PHARMACOL. 114:P411-P411.
• LALIES MD; NUTT DJ. (Apr 1995). THE EFFECT OF A SELECTIVE I2-SITE LIGAND, 2-(-2-BENZOFURANYL)-2-IMIDAZOLINE, ON IN-VIVO NORADRENALINE RELEASE IN RAT-BRAIN. BRIT J PHARMACOL. 114:P413-P413.
• Carpéné C; Collon P; Remaury A; Cordi A; Hudson A; Nutt D; Lafontan M. (Feb 1995). Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J Pharmacol Exp Ther. 272:681-688.
• George DT; Nutt DJ; Rawlings RR; Phillips MJ; Eckardt MJ; Potter WZ; Linnoila M. (15 Jan 1995). Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism. Biol Psychiatry. 37:112-119. DOI.
• WEINSTEIN AM; NUTT DJ. (1995). A COGNITIVE DYSFUNCTION IN ANXIETY AND ITS AMELIORATION BY EFFECTIVE TREATMENT WITH SSRIS. J PSYCHOPHARMACOL. 9:83-89.
• Malizia A; Forse F; Haida A; Gunn R; Melichar J; Poole K; Bateman D; Fahy D; et alSchnorr L; Brown D; Rhodes C; Nutt DJ; Jones T. (1995). A new human (psycho)pharmacology tool: The multiple organs coincidences counter (MOCC). J PSYCHOPHARMACOL. 9:294-306.
• Malizia AL; Coupland NJ; Nutt DJ. (1995). Benzodiazepine receptor function in anxiety disorders. Adv Biochem Psychopharmacol. 48:115-133.
• JORDAN S; JACKSON HC; NUTT DJ; HANDLEY SL. (1995). DISCRIMINATIVE STIMULUS PROPERTIES OF ETHOXY IDAZOXAN. J PSYCHOPHARMACOL. 9:228-233.
• NUTT DJ. (1995). EDITORIAL - VENLAFAXINE - THE YIN AND YANG OF ANTIDEPRESSANTS. J PSYCHOPHARMACOL. 9:205-206.
• NUTT D. (1995). NEW APPROACHES TO ALCOHOL-WITHDRAWAL. J PSYCHOPHARMACOL. 9:75-75.
• Nutt DJ. (1995). Psychopharmacological imaging. J PSYCHOPHARMACOL. 9:293-293.
• BAILEY JE; POTOKAR J; COUPLAND N; NUTT DJ. (1995). THE 5-HT3 ANTAGONIST ONDANSETRON REDUCES GASTROINTESTINAL SIDE-EFFECTS INDUCED BY A SPECIFIC SEROTONIN REUPTAKE INHIBITOR IN MAN. J PSYCHOPHARMACOL. 9:137-141.
• NUTT D. (1995). THE ANXIETY FACTOR IN DEPRESSION. J PSYCHOPHARMACOL. 9:185-189.
• GLUE P; WILSON S; COUPLAND N; BALL D; NUTT D. (Jan 1995). THE RELATIONSHIP BETWEEN BENZODIAZEPINE RECEPTOR SENSITIVITY AND NEUROTICISM. J ANXIETY DISORD. 9:33-45.
• Nutt DJ; Wilson SJ; Coupland NJ. (Jan 1995). Use of selective serotonin reuptake inhibitors and other serotonergic drugs in the biological dissection of affective disorders. Int Clin Psychopharmacol. 9 Suppl 4:53-59.
• Nutt DJ. (1995). Venlaxine: The yin and yang of antidepressants (vol 9, pg 205, 1995). J PSYCHOPHARMACOL. 9:402-402.
• WILSON SW; LILLYWHITE AR; NUTT DJ. (Dec 1994). NIGHT TERRORS - REPLY. BRIT J PSYCHIAT. 165:835-835.
• Coupland NJ; Bailey JE; Wilson SJ; Potter WZ; Nutt DJ. (Oct 1994). A pharmacodynamic study of the alpha 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers. Clin Pharmacol Ther. 56:420-429.
• Thomas DN; Nutt D; Holman RB. (11 Aug 1994). Regionally specific changes in extracellular noradrenaline following chronic idazoxan as revealed by in vivo microdialysis. Eur J Pharmacol. 261:53-57.
• Smith J; Williams K; Birkett S; Nicholson H; Glue P; Nutt DJ. (Aug 1994). Neuroendocrine and clinical effects of electroconvulsive therapy and their relationship to treatment outcome. Psychol Med. 24:547-555.
• Arnott S; Nutt D. (Jun 1994). Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry. 164:838-839.
• HUDSON AL; HUSBANDS S; LEWIS JW; NUTT DJ. (May 1994). AFFINITY AND SELECTIVITY OF BU224 AND BU239 FOR RABBIT BRAIN NON-ADRENOCEPTOR IDAZOXAN BINDING-SITES (I-2-SITES). BRIT J PHARMACOL. 112:U162-U162.
• POTOKAR J; NUTT DJ. (Apr 1994). ANXIOLYTIC POTENTIAL OF BENZODIAZEPINE RECEPTOR PARTIAL AGONISTS. CNS DRUGS. 1:305-315.
• Lillywhite AR; Wilson SJ; Nutt DJ. (Apr 1994). Successful treatment of night terrors and somnambulism with paroxetine. Br J Psychiatry. 164:551-554.
• FRENCH N; LALIES MD; NUTT DJ; PRATT JA. (Jan 1994). A COMPARISON OF THE EFFECT OF IDAZOXAN ON NORADRENALINE RELEASE IN FREELY-MOVING AND PARTIALLY RESTRAINED RATS. BRIT J PHARMACOL. 111:P296-P296.
• NUTT DJ; PETERS TJ. (Jan 1994). ALCOHOL - THE DRUG. BRIT MED BULL. 50:5-17.
• Nutt DJ; Peters TJ. (Jan 1994). Alcohol: the drug. Br Med Bull. 50:5-17.
• NUTT D. (1994). NEW APPROACHES TO DRUG DEPENDENCY. J PSYCHOPHARMACOL. 8:68-68.
• NUTT D. (1994). PSYCHOTROPIC-DRUG DEVELOPMENT - SOCIAL, SCIENTIFIC AND ECONOMIC-ISSUES BAP AUTUMN MEETING, NOVEMBER 1993. J PSYCHOPHARMACOL. 8:136-138.
• NUTT DJ. (1994). PUTTING THE A IN ATYPICAL - DOES ALPHA(2)-ADRENOCEPTOR ANTAGONISM ACCOUNT FOR THE THERAPEUTIC ADVANTAGE OF NEW ANTIPSYCHOTICS. J PSYCHOPHARMACOL. 8:193-195.
• MONTGOMERY SA; HENRY J; MCDONALD G; DINAN T; LADER M; HINDMARCH I; CLARE A; NUTT D. (1994). SELECTIVE SEROTONIN REUPTAKE INHIBITORS - METAANALYSIS OF DISCONTINUATION RATES (VOL 9, PG 50, 1994). INT CLIN PSYCHOPHARM. 9:U1-U1.
• Montgomery SA; Henry J; McDonald G; Dinan T; Lader M; Hindmarch I; Clare A; Nutt D. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 9:47-53.
• ALLEN D; HORVATH R; NUTT D. (Sep 1993). ANTIDEPRESSANTS AND MANIA - TO STOP OR NOT TO STOP. HUM PSYCHOPHARM CLIN. 8:357-360.
• LALIES MD; NUTT DJ. (Jul 1993). A MICRODIALYSIS STUDY OF THE NEUROCHEMICAL EFFECTS IN RAT STRIATUM OF RX821039, A SELECTIVE LIGAND FOR NON-ADRENOCEPTOR IDAZOXAN BINDING-SITES. BRIT J PHARMACOL. 109:P85-P85.
• Jackson HC; Nutt DJ. (Jul 1993). A single preexposure produces sensitization to the locomotor effects of cocaine in mice. Pharmacol Biochem Behav. 45:733-735.
• Jackson HC; Griffin IJ; Nutt DJ. (Jul 1993). Buprenorphine-cocaine interactions in mice: effect on locomotor activity and hole-dipping behaviour. J Pharm Pharmacol. 45:636-640.
• HUDSON AL; NUTT DJ; LEWIS JW; MALLARD NJ; CHAPLEO CB. (Jul 1993). NEW 2-IODO SUBSTITUTED DERIVATIVES OF IDAZOXAN WITH HIGH-AFFINITY FOR MAMMALIAN ALPHA(2)-ADRENOCEPTORS. BRIT J PHARMACOL. 109:P24-P24.
• Pike VW; Halldin C; Crouzel C; Barré L; Nutt DJ; Osman S; Shah F; Turton DR; et alWaters SL. (May 1993). Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status. Nucl Med Biol. 20:503-525.
• PIKE VW; HALLDIN C; CROUZEL C; BARRE L; NUTT DJ; OSMAN S; SHAH F; TURTON DR; et alWATERS SL. (May 1993). RADIOLIGANDS FOR PET STUDIES OF CENTRAL BENZODIAZEPINE RECEPTORS AND PK (PERIPHERAL BENZODIAZEPINE) BINDING-SITES - CURRENT STATUS. NUCL MED BIOL. 20:503-525.
• Nutt DJ. (Apr 1993). The approach to new anxiolytics. J Pharm Pharmacol. 45 Suppl 1:352-354.
• Jordan S; Jackson HC; Nutt DJ; Handley SL. (1993). Central alpha-2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm. Psychopharmacology (Berl). 110:209-212.
• ALLEN D; NUTT D. (1993). COEXISTENCE OF PANIC DISORDER AND SLEEP PARALYSIS. J PSYCHOPHARMACOL. 7:293-294.
• Nutt D; Glue P; Wilson S; Groves S; Coupland N; Bailey J. (1993). Flumazenil in alcohol withdrawal. Alcohol Alcohol Suppl. 2:337-341.
• Jackson HC; Nutt DJ. (1993). Investigation of the involvement of opioid receptors in the action of anticonvulsants. Psychopharmacology (Berl). 111:486-490.
• Wilson SJ; Glue P; Ball D; Nutt DJ. (Jan 1993). Saccadic eye movement parameters in normal subjects. Electroencephalogr Clin Neurophysiol. 86:69-74.
• NUTT DJ; DEAKIN JFW; CROW TJ. (1993). THE PSYCHOPHARMACOLOGY OF SOCIAL COMMUNICATION AND ITS DISORDERS. J PSYCHOPHARMACOL. 7:226-229.
• Jackson HC; Nutt DJ. (Nov 1992). Are 5-HT receptors or beta-adrenoceptors involved in idazoxan-induced food and water intake?. Neuropharmacology. 31:1081-1087.
• Hume SP; Lammertsma AA; Opacka-Juffry J; Ahier RG; Myers R; Cremer JE; Hudson AL; Nutt DJ; et alPike VW. (Nov 1992). Quantification of in vivo binding of [3H]RX 821002 in rat brain: evaluation as a radioligand for central alpha 2-adrenoceptors. Int J Rad Appl Instrum B. 19:841-849.
• Jackson HC; Nutt DJ. (20 Oct 1992). Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice. Eur J Pharmacol. 221:199-203.
• Mallard NJ; Hudson AL; Nutt DJ. (Aug 1992). Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br J Pharmacol. 106:1019-1027.
• Jackson HC; Griffin IJ; Nutt DJ. (Aug 1992). Endogenous opioids may be involved in idazoxan-induced food intake. Neuropharmacology. 31:771-776.
• Jackson HC; Ramsay E; Nutt DJ. (Jul 1992). Attenuation of the behavioural effects of ethanol in mice by des-enkephalin-gamma-endorphin (ORG 5878). Alcohol Alcohol. 27:373-379.
• JORDAN S; JACKSON HC; NUTT DJ; HANDLEY SL. (Jul 1992). THE DISCRIMINATORY STIMULUS (CUE) TO CLONIDINE APPEARS TO BE MEDIATED BY ITS ALPHA-2-ADRENOCEPTOR AGONIST PROPERTIES. BRIT J PHARMACOL. 106:P131-P131.
• Williams K; Smith J; Glue P; Nutt D. (Jul 1992). The effects of electroconvulsive therapy on plasma insulin and glucose in depression. Br J Psychiatry. 161:94-98.
• Thomas DN; Nutt DJ; Holman RB. (Jun 1992). Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol. 106:430-434.
• Jackson HC; Griffin IJ; Birkett SD; Nutt DJ. (Jun 1992). The effects of idazoxan and other alpha 2-adrenoceptor antagonists on urine output in the rat. Br J Pharmacol. 106:443-446.
• Jackson HC; Ramsay E; Nutt DJ. (27 May 1992). Effect of the cyclopyrrolones suriclone and RP 59037 on body temperature in mice. Eur J Pharmacol. 216:23-27.
• Glue P; Wilson S; Campling GM; Knightly M; Franklin M; Cowen PJ; Nutt DJ. (May 1992). Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology. 17:261-266.
• NUTT DJ; GLUE P; WILSON S. (Apr 1992). CHRONIC USE OF ALCOHOL AND OR BENZODIAZEPINES MAY ACCOUNT FOR EVIDENCE OF ALTERED BENZODIAZEPINE RECEPTOR SENSITIVITY IN PANIC DISORDER - REPLY. ARCH GEN PSYCHIAT. 49:330-331.
• Nutt D; Lawson C. (Feb 1992). Panic attacks. A neurochemical overview of models and mechanisms. Br J Psychiatry. 160:165-178.
• NUTT DJ; GROVES S. (Jan 1992). A DOUBLE-BLIND COMPARISON OF ACUTE BUPRENORPHINE WITH PLACEBO IN SCHIZOPHRENIA. SCHIZOPHR RES. 6:113-113.
• Jackson HC; Griffin IJ; Nutt DJ. (1992). Alpha 2-adrenoceptor antagonists block the stimulant effects of cocaine in mice. Life Sci. 50:PL155-PL159.
• Coupland N; Glue P; Nutt DJ. (1992). Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders. Mol Aspects Med. 13:221-247.
• Nutt DJ; Glue P; Wilson S; Coupland N; Lillywhite A. (1992). Clinical correlates of benzodiazepine receptor function. Clin Neuropharmacol. 15 Suppl 1 Pt A:679A-680A.
• WILSON S; GLUE P; NUTT D. (Jan 1992). FLUMAZENIL AND SACCADIC EYE-MOVEMENTS IN PATIENTS WITH PANIC DISORDER AND NORMAL CONTROLS. HUM PSYCHOPHARM CLIN. 7:45-50.
• Nutt DJ; Smith CF; Bennett R; Jackson HC. (1992). Investigations on the "set-point" theory of benzodiazepine receptor function. Adv Biochem Psychopharmacol. 47:419-429.
• NUTT DJ; SMITH CF; BENNETT R; JACKSON HC. (1992). INVESTIGATIONS ON THE SET-POINT THEORY OF BENZODIAZEPINE RECEPTOR FUNCTION. ADV BIOCHEM PSYCHOPH. 47:419-429.
• Nutt DJ. (1992). Pharmacoendocrine studies in anxiety. Clin Neuropharmacol. 15 Suppl 1 Pt A:214A-215A.
• Jackson HC; Nutt DJ. (1992). Strain differences in sensitivity to the hypothermic effects of benzodiazepine receptor ligands in mice. Psychopharmacology (Berl). 109:365-368.
• Glue P; Bailey J; Wilson S; Hudson A; Nutt DJ. (1992). Thyrotropin-releasing hormone selectively reverses lorazepam-induced sedation but not slowing of saccadic eye movements. Life Sci. 50:PL25-PL30.
• Lamparski DM; Roy A; Nutt DJ; Linnoila M. (Dec 1991). The criteria of Cloninger et al. and von Knorring et al. for subgrouping alcoholics: a comparison in a clinical population. Acta Psychiatr Scand. 84:497-502.
• Jackson HC; Nutt DJ. (26 Nov 1991). Comparison of the effects of benzodiazepine and beta-carboline inverse agonists on body temperature in mice. Eur J Pharmacol. 205:213-216.
• NUTT D. (Oct 1991). STRESSORS AND THE ADJUSTMENT DISORDERS - NOSHPITZ,JD, CODDINGTON,RD. STRESS MEDICINE. 7:261-261.
• Jackson HC; Nutt DJ. (Sep 1991). Investigation of the different types of opioid receptor involved in electroconvulsive shock-induced antinociception and catalepsy in the rat. J Pharm Pharmacol. 43:640-643.
• Jackson HC; Griffin IJ; Nutt DJ. (Sep 1991). The effects of idazoxan and other alpha 2-adrenoceptor antagonists on food and water intake in the rat. Br J Pharmacol. 104:258-262.
• Adinoff B; Risher-Flowers D; De Jong J; Ravitz B; Bone GH; Nutt DJ; Roehrich L; Martin PR; et alLinnoila M. (Aug 1991). Disturbances of hypothalamic-pituitary-adrenal axis functioning during ethanol withdrawal in six men. Am J Psychiatry. 148:1023-1025.
• Jackson HC; Ripley TL; Dickinson SL; Nutt DJ. (Jul 1991). Anticonvulsant activity of the imidazoline 6,7-benzoidazoxan. Epilepsy Res. 9:121-126.
• Jackson HC; Nutt DJ. (May 1991). Inhibition of baclofen-induced hypothermia in mice by the novel GABAB antagonist CGP 35348. Neuropharmacology. 30:535-538.
• Benkelfat C; Murphy DL; Hill JL; George DT; Nutt D; Linnoila M. (Apr 1991). Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 48:383.
• Hart YM; Meinardi H; Sander JW; Nutt DJ; Shorvon SD. (Apr 1991). The effect of intravenous flumazenil on interictal electroencephalographic epileptic activity: results of a placebo-controlled study. J Neurol Neurosurg Psychiatry. 54:305-309.
• Hart YM; Sander JW; Meinardi H; Nutt DJ; Shorvon SD. (23 Mar 1991). Flumazenil as an anti-epileptic agent. Lancet. 337:744.
• Glue P; Nutt DJ. (2 Mar 1991). Benzodiazepine receptor sensitivity in panic disorder. Lancet. 337:563.
• GROVES S; NUTT D. (Mar 1991). BUPRENORPHINE AND SCHIZOPHRENIA. HUM PSYCHOPHARM CLIN. 6:71-72.
• NUTT DJ; GLUE P. (Mar 1991). IRRITABILITY IN PANIC DISORDER - EFFECTS OF IMIPRAMINE TREATMENT. HUM PSYCHOPHARM CLIN. 6:49-52.
• Jackson HC; Nutt DJ. (7 Feb 1991). Effect of benzodiazepine and beta-carboline antagonists and partial agonists on loprazolam- and ZK 93423-induced hypothermia. Eur J Pharmacol. 193:179-184.
• Jackson HC; Nutt DJ. (1991). Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice. Psychopharmacology (Berl). 103:380-383.
• Jackson HC; Weinberger PJ; Nutt DJ. (1991). Do Opioid, alpha(2)-Adrenoreceptors, or Benzodiazepine Receptors Mediate ECS-Induced Hypothermia in Mice?. Convuls Ther. 7:20-27.
• Glue P; Payvandi N; Kay G; Elliott JM; Nutt DJ. (1991). Effects of chronic alpha 2-adrenoceptor blockade on platelet and lymphocyte adrenoceptor binding in normal volunteers. Life Sci. 49:PL21-PL25.
• Jackson HC; Dickinson SL; Nutt DJ. (1991). Exploring the pharmacology of the pro-convulsant effects of alpha 2-adrenoceptor antagonists in mice. Psychopharmacology (Berl). 105:558-562.
• Ball DM; Glue P; Wilson S; Nutt DJ. (1991). Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. Psychopharmacology (Berl). 105:361-367.
• Glue P; White E; Wilson S; Ball DM; Nutt DJ. (1991). Pharmacology of saccadic eye movements in man. 2. Effects of the alpha 2-adrenoceptor ligands idazoxan and clonidine. Psychopharmacology (Berl). 105:368-373.
• Nutt D. (6 Oct 1990). Closure of MRC units. Lancet. 336:884.
• Nutt DJ; Glue P; Lawson C; Wilson S. (Oct 1990). Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 47:917-925.
• Glue P; Nutt D. (Oct 1990). Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. Br J Psychiatry. 157:491-499.
• Jackson HC; Nutt DJ. (28 Aug 1990). Body temperature discriminates between full and partial benzodiazepine receptor agonists. Eur J Pharmacol. 185:243-246.
• NUTT DJ. (Aug 1990). BEHAVIOR, AUTONOMIC FUNCTION AND THE BRAIN. CURR OPIN NEUROL NEU. 3:507-511.
• Weiss SR; Post RM; Costello M; Nutt DJ; Tandeciarz S. (Aug 1990). Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity. Neuropsychopharmacology. 3:273-281.
• George DT; Adinoff B; Ravitz B; Nutt DJ; De Jong J; Berrettini W; Mefford IN; Costa E; et alLinnoila M. (Jul 1990). A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatr Scand. 82:1-7.
• GEORGE DT; NUTT DJ; WAXMAN RP; LINNOILA M. (Jun 1990). RESPONSE OF ALCOHOLIC AND NONALCOHOLIC PANIC PATIENTS TO LACTATE INFUSION - REPLY. AM J PSYCHIAT. 147:819-820.
• Smith JE; Williams K; Burkett S; Glue P; Nutt DJ. (May 1990). Oxytocin and vasopressin responses to ECT. Psychiatry Res. 32:201-202.
• NUTT D. (Apr 1990). NOT ONLY BUT ALSO - COMMENTS. NEUROPSYCHOPHARMACOL. 3:93-95.
• Nutt D. (Apr 1990). Not only but also? Comments on "How does convulsive therapy work"?. Neuropsychopharmacology. 3:93-95.
• Peeters BW; Van Rijn CM; Nutt DJ; Titulaer MN; Vossen JM; Coenen AM. (13 Mar 1990). Diazepam and Ro 15-1788 increase absence epilepsy in WAG/Rij rats chronically exposed to diazepam. Eur J Pharmacol. 178:111-114.
• Glue P; Nutt DJ. (Mar 1990). Lithium treatment effect on serotonin function. Arch Gen Psychiatry. 47:289-290.
• George DT; Nutt DJ; Dwyer BA; Linnoila M. (Feb 1990). Alcoholism and panic disorder: is the comorbidity more than coincidence?. Acta Psychiatr Scand. 81:97-107.
• Roy A; Lamparski D; De Jong J; Adinoff B; Ravitz B; George DT; Nutt D; Linnoila M. (Jan 1990). Cerebrospinal fluid monoamine metabolites in alcoholic patients who attempt suicide. Acta Psychiatr Scand. 81:58-61.
• George DT; Glue P; Bacher JD; Waxman RP; Nutt DJ. (1 Jan 1990). Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits. Biol Psychiatry. 27:104-108.
• Nutt DJ; Glue P. (1990). Neuropharmacological and clinical aspects of alcohol withdrawal. Ann Med. 22:275-281.
• Jackson HC; Ball DM; Nutt DJ. (1990). Noradrenergic mechanisms appear not to be involved in cocaine-induced seizures and lethality. Life Sci. 47:353-359.
• Nutt DJ. (1990). Pharmacological mechanisms of benzodiazepine withdrawal. J Psychiatr Res. 24 Suppl 2:105-110.
• Glue P; Costello MJ; Pert A; Mele A; Nutt DJ. (1990). Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl). 100:60-65.
• Nutt DJ; Glue P; Lawson C. (1990). The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry. 14:737-752.
• Nutt DJ. (1990). The pharmacology of human anxiety. Pharmacol Ther. 47:233-266.
• Jackson HC; Ripley TL; Nutt DJ. (Dec 1989). Exploring delta-receptor function using the selective opioid antagonist naltrindole. Neuropharmacology. 28:1427-1430.
• George DT; Nutt DJ; Waxman RP; Linnoila M. (Sep 1989). Panic response to lactate administration in alcoholic and nonalcoholic patients with panic disorder. Am J Psychiatry. 146:1161-1165.
• Nutt D; Lawson C; Glue P. (Aug 1989). Attitudes to anxiety. Br J Psychiatry. 155:268.
• Nutt DJ; Lister RG. (8 Jun 1989). 3-(Methoxycarbonyl)-amino-beta-carboline reduces both the sedative and anticonvulsant effects of diazepam. Eur J Pharmacol. 165:135-138.
• NUTT DJ. (Jun 1989). ENDOCRINE RESPONSE TO SYNCOPE IN PANIC DISORDER. PSYCHIAT RES. 28:352-353.
• George DT; Anderson P; Nutt DJ; Linnoila M. (May 1989). Aggressive thoughts and behavior: another symptom of panic disorder?. Acta Psychiatr Scand. 79:500-502.
• Gleiter CH; Linnoila M; Nutt DJ. (Apr 1989). Low affinity hypothalamic [3H]mazindol binding: a probe for hypothalamic body weight regulation?. Appetite. 12:137-143.
• Nutt D; Glue P. (Mar 1989). Monoamine oxidase inhibitors: rehabilitation from recent research?. Br J Psychiatry. 154:287-291.
• Nutt DJ. (Feb 1989). Altered central alpha 2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry. 46:165-169.
• Gleiter CH; Deckert J; Nutt DJ; Marangos PJ. (Feb 1989). Electroconvulsive shock (ECS) and the adenosine neuromodulatory system: effect of single and repeated ECS on the adenosine A1 and A2 receptors, adenylate cyclase, and the adenosine uptake site. J Neurochem. 52:641-646.
• George DT; Nutt DJ; Walker WV; Porges SW; Adinoff B; Linnoila M. (Feb 1989). Lactate and hyperventilation substantially attenuate vagal tone in normal volunteers. A possible mechanism of panic provocation?. Arch Gen Psychiatry. 46:153-156.
• GLEITER CH; DECKERT J; NUTT DJ; MARANGOS PJ. (Feb 1989). LONG-LASTING ADENOSINE A1 RECEPTOR UPREGULATION IN RAT CEREBRAL-CORTEX AFTER CHRONIC ELECTROCONVULSIVE SHOCK (ECS). CLIN PHARMACOL THER. 45:172-172.
• Bone GH; Majchrowicz E; Martin PR; Linnoila M; Nutt DJ. (1989). A comparison of calcium antagonists and diazepam in reducing ethanol withdrawal tremors. Psychopharmacology (Berl). 99:386-388.
• Lister RG; Durcan MJ; Nutt DJ; Linnoila M. (1989). Attenuation of ethanol intoxication by alpha-2 adrenoceptor antagonists. Life Sci. 44:111-119.
• Nutt D; Adinoff B; Linnoila M. (1989). Benzodiazepines in the treatment of alcoholism. Recent Dev Alcohol. 7:283-313.
• Gleiter CH; Nutt DJ. (1989). Chronic electroconvulsive shock and neurotransmitter receptors--an update. Life Sci. 44:985-1006.
• Nutt DJ; Glue P. (1989). Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacol Ther. 44:309-334.
• Gleiter CH; Costello MJ; Nutt DJ. (1989). Effect of Single and Repeated Electroconvulsive Shock on Body Temperature in Mice. Convuls Ther. 5:152-156.
• Thiagarajan AB; Gleiter CH; Mefford IN; Eskay RL; Nutt DJ. (1989). Effect of single and repeated electroconvulsive shock on the hypothalamic-pituitary-adrenal axis and plasma catecholamines in rats. Psychopharmacology (Berl). 97:548-552.
• Nutt DJ; Gleiter CH; Glue P. (1989). Neuropharmacological Aspects of ECT: In Search of the Primary Mechanism of Action. Convuls Ther. 5:250-260.
• Glue P; Sellman JD; Nicholls MG; Abbott R; Joyce PR; Nutt DJ. (Jan 1989). Studies of alpha-2-adrenoceptor function in abstinent alcoholics. Br J Addict. 84:97-102.
• Glue P; Bacher JD; Nutt DJ. (Dec 1988). A technique for chronic catheterization of the cisterna magna in rabbits. Lab Anim Sci. 38:740-742.
• Nutt DJ; Linnoila M. (Dec 1988). Neuroreceptor science: a clarification of terms. J Clin Psychopharmacol. 8:387-389.
• Nutt DJ; Lister RG. (Nov 1988). Antagonizing the anticonvulsant effect of ethanol using drugs acting at the benzodiazepine/GABA receptor complex. Pharmacol Biochem Behav. 31:751-755.
• LISTER RG; NUTT DJ. (Nov 1988). ANTAGONIZING THE BEHAVIORAL-EFFECTS OF ETHANOL USING DRUGS THAT ACT AT THE BENZODIAZEPINE GABA RECEPTOR MACROMOLECULAR COMPLEX - PROCEEDINGS OF A SATELLITE SYMPOSIUM TO THE 17TH ANNUAL-MEETING OF THE SOCIETY-FOR-NEUROSCIENCE - NEW-ORLEANS, LA, NOVEMBER 15, 1987 - INTRODUCTION. PHARMACOL BIOCHEM BE. 31:731-731.
• Gleiter CH; Deckert J; Nutt DJ; Marangos PJ. (Nov 1988). The effect of acute and chronic electroconvulsive shock on [3H]phorbol-dibutyrate binding to rat brain membranes. Neurochem Res. 13:1023-1026.
• Lister RG; Nutt DJ. (Aug 1988). Alcohol antagonists--the continuing quest. Alcohol Clin Exp Res. 12:566-569.
• Nutt DJ; Lister RG; Rusche D; Bonetti EP; Reese RE; Rufener R. (22 Jun 1988). RO 15-4513 does not protect rats against the lethal effects of ethanol. Eur J Pharmacol. 151:127-129.
• George DT; Zerby A; Noble S; Nutt DJ. (Jun 1988). Panic attacks and alcohol withdrawal: can subjects differentiate the symptoms?. Biol Psychiatry. 24:240-243.
• Nutt DJ; Gleiter CH; Linnoila M. (17 May 1988). Repeated electroconvulsive shock normalizes blood glucose levels in genetically obese mice (C57BL/6J ob/ob) but not in genetically diabetic mice (C57BL/KsJ db/db). Brain Res. 448:377-380.
• Glue P; Sellman JD; Joyce PR; Nicholls MG; Nutt DJ. (May 1988). The hypothermic response to clonidine is absent in alcohol withdrawal but returns in abstinence. Biol Psychiatry. 24:102-104.
• RISHERFLOWERS D; BONE G; RAVITZ B; MARTIN PR; ADINOFF B; GEORGE DT; MOSS H; GOLD P; et alNUTT DJ; LINNOILA M. (Apr 1988). ARE VASOPRESSIN RESPONSES TO OSMOTIC LOAD REDUCED IN ALCOHOLIC MEN. ALCOHOL CLIN EXP RES. 12:336-336.
• Little HJ; Gale R; Sellars N; Nutt DJ; Taylor SC. (Apr 1988). Chronic benzodiazepine treatment increases the effects of the inverse agonist FG7142. Neuropharmacology. 27:383-389.
• Nutt D. (Mar 1988). Benzodiazepine terminology. Trends Pharmacol Sci. 9:86.
• Nutt D; Glue P; Molyneux S; Clark E. (Feb 1988). Alpha-2-adrenoceptor function in alcohol withdrawal: a pilot study of the effects of iv. clonidine in alcoholics and normals. Alcohol Clin Exp Res. 12:14-18.
• GLEITER CH; THIAGARAJAN AB; NUTT DJ. (Feb 1988). AN ANIMAL-MODEL FOR THE CNS ACTIONS OF ELECTRO-CONVULSIVE SHOCK (ECS). CLIN PHARMACOL THER. 43:177-177.
• Gleiter CH; Nutt DJ. (1988). A single electroconvulsive shock substantially lowers blood glucose levels in obese mice (C57BL/6J ob/ob). Psychopharmacology (Berl). 95:287-288.
• Nutt DJ; Taylor SC; Little HJ; Standing BL; Gale RG. (1988). Changes in benzodiazepine/GABA receptor complex function in benzodiazepine-tolerant mice. Psychopharmacology (Berl). 95:407-412.
• Gleiter CH; Deckert J; Nutt DJ. (1988). Changes in caffeine seizure threshold after electroconvulsive shock. Psychopharmacology (Berl). 95:544-545.
• Risher-Flowers D; Adinoff B; Ravitz B; Bone GH; Martin PR; Nutt D; Linnoila M. (1988). Circadian rhythms of cortisol during alcohol withdrawal. Adv Alcohol Subst Abuse. 7:37-41. DOI.
• Thiagarajan AB; Gleiter CH; Nutt DJ. (1988). Electroconvulsive Shock Does Not Increase Plasma Insulin in Rats. Convuls Ther. 4:292-296.
• Lister RG; Nutt DJ. (Jan 1988). Interactions of the imidazodiazepine Ro 15-4513 with chemical convulsants. Br J Pharmacol. 93:210-214.
• LISTER RG; DURCAN MJ; NUTT DJ; LINNOILA M. (1988). PHARMACOLOGICAL ANTAGONISM OF ETHANOLS BEHAVIORAL-EFFECTS - A COMPARISON BETWEEN BENZODIAZEPINE RECEPTOR INVERSE AGONISTS AND ALPHA-2 RECEPTOR ANTAGONISTS. PSYCHOPHARMACOLOGY. 96:S35-S35.
• Nutt DJ; Costello MJ. (1988). Rapid induction of lorazepam dependence and reversal with flumazenil. Life Sci. 43:1045-1053.
• Gleiter CH; Nutt DJ. (1988). Repeated electroconvulsive shock does not change [3H]-paroxetine binding to the 5-HT uptake site in rat cortical membranes. Psychopharmacology (Berl). 95:68-70.
• Gleiter CH; Nutt DJ. (1988). Repeated electroconvulsive shock increases the number of [3H]desipramine binding sites in rat cerebral cortex. Psychopharmacology (Berl). 96:426-427.
• Lister RG; Nutt DJ. (1988). RO 15-4513 and its interaction with ethanol. Adv Alcohol Subst Abuse. 7:119-123. DOI.
• NUTT DJ; LISTER RG. (1988). STRAIN DIFFERENCES IN RESPONSE TO A BENZODIAZEPINE RECEPTOR INVERSE AGONIST (FG 7142) IN MICE. PSYCHOPHARMACOLOGY. 94:435-436.
• Nutt DJ; Lister RG. (1988). Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. Psychopharmacology (Berl). 94:335-336.
• LINNOILA M; MEFFORD I; NUTT D; ADINOFF B. (Dec 1987). ALCOHOL-WITHDRAWAL AND NORADRENERGIC FUNCTION. ANN INTERN MED. 107:875-889.
• Linnoila M; Mefford I; Nutt D; Adinoff B. (Dec 1987). NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med. 107:875-889.
• Nutt D; Glue P; Stewart A. (Nov 1987). Platelet monamine receptor binding in alcoholics during withdrawal. Br J Addict. 82:1253-1255.
• GLEITER CH; NUTT DJ; COSTELLO M; LINNOILA M. (Sep 1987). ANTIDIABETIC EFFECT OF ELECTROSHOCK (ECS) IN OB/OB MICE. J CLIN PHARMACOL. 27:716-716.
• Little HJ; Nutt DJ; Taylor SC. (Sep 1987). Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. Brain Res Bull. 19:371-378.
• NUTT D; COSTELLO M. (22 Aug 1987). FLUMAZENIL AND BENZODIAZEPINE WITHDRAWAL. LANCET. 2:463-463.
• Nutt DJ; Cowen PJ. (Aug 1987). Diazepam alters brain 5-HT function in man: implications for the acute and chronic effects of benzodiazepines. Psychol Med. 17:601-607.
• George DT; Ladenheim JA; Nutt DJ. (Aug 1987). Effect of pregnancy on panic attacks. Am J Psychiatry. 144:1078-1079.
• Nutt DJ. (Jul 1987). Platelet alpha 2-adrenoceptor binding does not predict brain alpha 2-adrenoceptor function. Br J Clin Pharmacol. 24:122-123.
• Nutt DJ; Lister RG. (9 Jun 1987). The effect of the imidazodiazepine Ro 15-4513 on the anticonvulsant effects of diazepam, sodium pentobarbital and ethanol. Brain Res. 413:193-196.
• NUTT DJ. (Jun 1987). ABNORMAL ALPHA-2-ADRENOCEPTOR-MEDICATED ENDOCRINE RESPONSE IN PANIC DISORDER. NEUROENDOCRINOL LETT. 9:210-210.
• LISTER RG; NUTT DJ. (Jun 1987). IS RO-15-4513 A SPECIFIC ALCOHOL ANTAGONIST. TRENDS NEUROSCI. 10:223-225.
• GEORGE DT; NUTT DJ; LINNOILA M. (Apr 1987). ARE ALCOHOLICS SUBSENSITIVE TO LACTATE. ALCOHOL CLIN EXP RES. 11:215-215.
• Nutt D; Molyneux S. (Apr 1987). Benzodiazepines, plasma MHPG and alpha-2-adrenoceptor function in man. Int Clin Psychopharmacol. 2:151-157.
• NUTT DJ; GLUE P. (Apr 1987). PHARMACOLOGICAL EVIDENCE OF KINDLING IN ALCOHOLICS. ALCOHOL CLIN EXP RES. 11:218-218.
• RAVITZ B; TOWLE M; NUTT D; LANE E; BOWEN B. (Apr 1987). PSYCHOLOGICAL EFFECTS OF ETHANOL IN NORMAL-MALE VOLUNTEERS. ALCOHOL CLIN EXP RES. 11:219-219.
• NUTT DJ; LISTER R. (Apr 1987). STUDIES ON THE PUTATIVE ALCOHOL ANTAGONIST RO15-4513. ALCOHOL CLIN EXP RES. 11:218-218.
• Stanford SC; Little HJ; Nutt DJ; Taylor SC. (24 Feb 1987). A single dose of FG 7142 causes long-term increases in mouse cortical beta-adrenoceptors. Eur J Pharmacol. 134:313-319.
• NUTT DJ; GLUE P. (Feb 1987). CLONIDINE RESPONSES IN ALCOHOL-WITHDRAWAL. CLIN PHARMACOL THER. 41:231-231.
• Glue P; Nutt D. (1987). Clonidine in alcohol withdrawal: a pilot study of differential symptom responses following i.v. clonidine. Alcohol Alcohol. 22:161-166.
• GLUE P; NUTT DJ; KOLAKOWSKA T; COWEN PJ. (Jan 1987). LITHIUM ENHANCES 5-HT-MEDIATED NEUROENDOCRINE RESPONSES IN MAN. BRIT J CLIN PHARMACO. 23:P108-P108.
• Nutt DJ; Fraser S. (Jan 1987). Platelet binding studies in panic disorder. J Affect Disord. 12:7-11.
• Little HJ; Nutt DJ; Taylor SC. (Jan 1987). Selective changes in the in vivo effects of benzodiazepine receptor ligands after chemical kindling with FG 7142. Neuropharmacology. 26:25-31.
• Glue PW; Nutt DJ; Cowen PJ; Broadbent D. (1987). Selective effect of lithium on cognitive performance in man. Psychopharmacology (Berl). 91:109-111.
• Idzikowski C; Cowen PJ; Nutt D; Mills FJ. (1987). The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology (Berl). 93:416-420.
• Nutt D; Middleton H; Franklin M. (1987). The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology. 12:367-375.
• Nutt D; Hackman A; Hawton K. (8 Nov 1986). Increased sexual function in benzodiazepine withdrawal. Lancet. 2:1101-1102.
• NUTT D. (Nov 1986). BENZODIAZEPINE DEPENDENCE IN THE CLINIC - REASON FOR ANXIETY. TRENDS PHARMACOL SCI. 7:457-460.
• LITTLE HJ; NUTT DJ; TAYLOR SC. (Oct 1986). A SHORT COURSE OF BENZODIAZEPINE TREATMENT, IN MICE, CAUSES A PROLONGED INCREASE IN SENSITIVITY TO BENZODIAZEPINE INVERSE AGONISTS. BRIT J ADDICT. 81:710-710.
• Stanford SC; Little HJ; Nutt DJ; Taylor SC. (23 Sep 1986). Effects of chronic treatment with benzodiazepine receptor ligands on cortical adrenoceptors. Eur J Pharmacol. 129:181-184.
• Nutt DJ; Taylor SC; Little HJ. (Sep 1986). Optimizing the pentetrazol infusion test for seizure threshold measurement. J Pharm Pharmacol. 38:697-698.
• Lister RG; Nutt DJ. (6 Aug 1986). Mice and rats are sensitized to the proconvulsant action of a benzodiazepine-receptor inverse agonist (FG 7142) following a single dose of lorazepam. Brain Res. 379:364-366.
• MIDDLETON HC; NUTT DJ. (Aug 1986). ARE THE CARDIOVASCULAR EFFECTS OF IMIPRAMINE CENTRALLY MEDIATED. BRIT J CLIN PHARMACO. 22:P221-P221.
• Brosan L; Broadbent D; Nutt D; Broadbent M. (Aug 1986). Performance effects of diazepam during and after prolonged administration. Psychol Med. 16:561-571.
• NUTT DJ; MOLYNEUX SJ. (Aug 1986). THE EFFECT OF DIAZEPAM ON PLASMA-FREE MHPG (3-METHOXY 4-HYDROXY PHENYLGLYCOL) IN MAN. BRIT J CLIN PHARMACO. 22:P230-P230.
• NUTT DJ; MIDDLETON HC; MURDOCK PJ; ARKINSTALL SY; FRANKLIN M. (Aug 1986). THE NEUROENDOCRINE EFFECTS OF ORAL IMIPRAMINE. BRIT J CLIN PHARMACO. 22:P222-P222.
• Little HJ; Nutt DJ; Taylor SC. (Jul 1986). The effects of drugs acting at the GABAA-receptor/ionophore after chemical kindling with the benzodiazepine receptor ligand FG 7142. Br J Pharmacol. 88:507-514.
• Nutt D; Glue P. (Jun 1986). Monoamines and alcohol. Br J Addict. 81:327-338.
• FRANKLIN M; NUTT DJ; MIDDLETON H; MURDOCK P; ARKINSTALL S. (1986). PLASMA GROWTH-HORMONE, PROLACTIN AND CORTISOL-LEVELS FOLLOWING ACUTE ORAL IMIPRAMINE ADMINISTRATION AT 2 DOSE LEVELS IN NORMAL SUBJECTS. ACTA PHARMACOL TOX. 59:211-211.
• NUTT DJ; FRANKLIN M; GOSDEN B; MURDOCK P. (May 1986). THE EFFECT OF DIAZEPAM ON INDEXES OF ALPHA-2-ADRENOCEPTOR FUNCTION IN MAN. BRIT J CLIN PHARMACO. 21:P588-P588.
• Nutt DJ; Cowen PJ; Franklin M; Murdock P; Gosden B; Fraser S. (May 1986). The effect of diazepam on indices of 5-HT function in man. Pharmacol Biochem Behav. 24:1491-1495.
• Nutt DJ; Little H. (Apr 1986). Benzodiazepine-receptor mediated convulsions in infant rats: effects of beta-carbolines. Pharmacol Biochem Behav. 24:841-844.
• Nutt DJ. (1986). Increased central alpha 2-adrenoceptor sensitivity in panic disorder. Psychopharmacology (Berl). 90:268-269.
• NUTT DJ; MOLYNEUX SG. (1986). STUDIES ON PLASMA-FREE MHPG (3-METHOXY-4-HYDROXY-PHENYLGLYCOL) AND THE CLONIDINE CHALLENGE TEST. INT J NEUROSCI. 31:130-131.
• Nutt DJ; Molyneux SG. (1986). The effect of clonidine on plasma MHPG: evidence against tonic alpha 2-adrenoceptor control of noradrenergic function. Psychopharmacology (Berl). 90:509-512.
• Glue PW; Cowen PJ; Nutt DJ; Kolakowska T; Grahame-Smith DG. (1986). The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology (Berl). 90:398-402.
• Quintero S; Mellanby J; Thompson MR; Nordeen H; Nutt D; McNaughton N; Gray JA. (Dec 1985). Septal driving of hippocampal theta rhythm: role of gamma-aminobutyrate-benzodiazepine receptor complex in mediating effects of anxiolytics. Neuroscience. 16:875-884.
• Little HJ; Taylor SC; Nutt DJ; Cowen PJ. (8 Jan 1985). The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in rats. Eur J Pharmacol. 107:375-377.
• Taylor SC; Little HJ; Nutt DJ; Sellars N. (Jan 1985). A benzodiazepine agonist and contragonist have hypothermic effects in rodents. Neuropharmacology. 24:69-73.
• NUTT D. (1985). ANXIOLYTICS - NEUROCHEMICAL, BEHAVIORAL AND CLINICAL PERSPECTIVE - MALICK,JB, ENNA,SJ, YAMAMURA,HI. BRIT J ADDICT. 80:327-328.
• NUTT DJ; FRASER S; GOSDEN B; STUMP K; ELLIOTT JM. (1985). BENZODIAZEPINES AND HUMAN-PLATELET RECEPTOR-BINDING. BRIT J CLIN PHARMACO. 19:P554-P555.
• NUTT D. (1985). CLINICAL BIOCHEMISTRY OF ALCOHOLISM - ROSALKI,SB. BRIT J ADDICT. 80:442-443.
• NUTT DJ; MOLYNEUX SG. (1985). PLASMA 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND THE CLONIDINE CHALLENGE TEST IN MAN. BRIT J CLIN PHARMACO. 20:P542-P543.
• MOLYNEUX SG; NUTT DJ. (1985). STUDIES ON PLASMA-FREE 3-METHOXY-4-HYDROXPHENYLGLYCOL IN MAN. BRIT J CLIN PHARMACO. 20:P541-P542.
• Little HJ; Nutt DJ; Taylor SC. (Dec 1984). Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling. Br J Pharmacol. 83:951-958.
• Minchin MC; Nutt DJ. (Oct 1984). The effect of repeated electroconvulsive shock on the function of THIP, a GABA agonist. Pharmacol Biochem Behav. 21:491-493.
• Nutt DJ; Little HJ; Taylor SC; Minchin MC. (17 Aug 1984). Investigating benzodiazepine receptor function in vivo using an intravenous infusion of DMCM. Eur J Pharmacol. 103:359-362.
• NUTT D; LITTLE H. (1984). KINDLING PRODUCED BY A BENZODIAZEPINE RECEPTOR CONTRAGONIST (INVERSE AGONIST). DEV NEUROSCI-AMSTER. 17:443-447.
• File SE; Green AR; Nutt DJ; Vincent ND. (1984). On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain. Psychopharmacology (Berl). 82:199-202.
• Minchin MC; Nutt DJ. (Dec 1983). Studies on [3H]diazepam and [3H]ethyl-beta-carboline carboxylate binding to rat brain in vivo. I. Regional variations in displacement. J Neurochem. 41:1507-1512.
• Nutt DJ; Minchin MC. (Dec 1983). Studies on [3H]diazepam and [3H]ethyl-beta-carboline carboxylate binding to rat brain in vivo. II. Effects of electroconvulsive shock. J Neurochem. 41:1513-1517.
• Atterwill CK; Nutt DJ. (Nov 1983). Thyroid hormones do not alter rat brain benzodiazepine receptor function in-vivo. J Pharm Pharmacol. 35:767-768.
• Heal DJ; O'Shaughnessy KM; Smith SL; Nutt DJ. (22 Apr 1983). Hypophysectomy alters both 5-hydroxytryptamine- and alpha 2-adrenoceptor-mediated behavioural changes in the rat. Eur J Pharmacol. 89:167-171.
• Stanford C; Nutt DJ; Cowen PJ. (Jan 1983). Comparison of the effects of chronic desmethylimipramine administration on alpha 2- and beta-adrenoceptors in different regions of rat brain. Neuroscience. 8:161-164.
• Nutt D. (1983). Pharmacological and behavioural studies of benzodiazepine antagonists and contragonists. Adv Biochem Psychopharmacol. 38:153-173.
• Bowdler JM; Green AR; Minchin MC; Nutt DJ. (1983). Regional GABA concentration and [3H]-diazepam binding in rat brain following repeated electroconvulsive shock. J Neural Transm. 56:3-12.
• File SE; Lister RG; Nutt DJ. (8 Oct 1982). Intrinsic actions of benzodiazepine antagonists. Neurosci Lett. 32:165-168.
• File SE; Lister RG; Nutt DJ. (Oct 1982). The anxiogenic action of benzodiazepine antagonists. Neuropharmacology. 21:1033-1037.
• Nutt DJ; Smith SL; Heal DJ. (Sep 1982). Hypophysectomy does not prevent the enhanced monoamine-mediated behavioural responses following repeated electroconvulsive shocks. Neuropharmacology. 21:881-884.
• Cowen PJ; Nutt DJ. (14 Aug 1982). Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism?. Lancet. 2:360-362.
• Stanford SC; Nutt DJ. (Jul 1982). Comparison of the effects of repeated electroconvulsive shock on alpha 2- and beta-adrenoceptors in different regions of rat brain. Neuroscience. 7:1753-1757.
• Nutt DJ; Cowen PJ; Little HJ. (4 Feb 1982). Unusual interactions of benzodiazepine receptor antagonists. Nature. 295:436-438.
• Nutt DJ; Cowen PJ; Batts CC; Grahame-Smith DG; Green AR. (1982). Repeated administration of subconvulsant doses of GABA antagonist drugs. I. Effect on seizure threshold (kindling). Psychopharmacology (Berl). 76:84-87.
• Cowen PJ; Nutt DJ; Batts CC; Green AR; Heal DJ. (1982). Repeated administration of subconvulsant doses of GABA antagonist drugs. II. Effect on monoamine-mediated behaviour. Psychopharmacology (Berl). 76:88-91.
• Green AR; Nutt DJ; Cowen PJ. (1982). Using Ro 15-1788 to investigate the benzodiazepine receptor in vivo: studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663. Psychopharmacology (Berl). 78:293-295.
• Nutt DJ; Cowen PJ; Green AR. (8 May 1981). Studies on the post-ictal rise in seizure threshold. Eur J Pharmacol. 71:287-295.
• Cowen PJ; Green AR; Nutt DJ. (5 Mar 1981). Ethyl beta-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats. Nature. 290:54-55.
• NUTT D; STANFORD C. (1981). DECREASED ALPHA-2-ADRENOCEPTOR NUMBERS IN RAT-BRAIN FOLLOWING REPEATED ELECTROCONVULSIVE SHOCK. BRIT J PHARMACOL. 74:P885-P886.
• COWEN PJ; GREEN AR; NUTT DJ. (1981). DRUG-INDUCED ALTERATIONS OF THE POST-ICTAL SEIZURE THRESHOLD INCREASE. BRIT J PHARMACOL. 73:P265-P266.
• NUTT D; STANFORD C. (1981). EFFECTS OF REPEATED ELECTROCONVULSIVE SHOCK ON BETA-ADRENERGIC RECEPTORS IN RAT-BRAIN. J PHYSIOL-LONDON. 320:P51-P51.
• Nutt DJ; Cowen PJ; Green AR. (Oct 1980). On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock. Neuropharmacology. 19:1017-1023.
• Cowen PJ; Nutt DJ; Green AR. (Oct 1980). Repeated electroconvulsive shock does not increase the susceptibility of rats to a cage convulsant (isopropylbicyclophosphate). Neuropharmacology. 19:1025-1026.
• Nutt DJ; Green AR; Grahame-Smith DG. (Sep 1980). Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions--I. The effects of single and repeated bicuculline-induced seizures. Neuropharmacology. 19:897-900.
• Cowen PJ; Nutt DJ; Green AR. (Sep 1980). Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions--II. The effects of anaesthesia and current conditions on the appearance of enhanced responses following electroconvulsive shock. Neuropharmacology. 19:901-906.
• GREEN AR; NUTT DJ. (1980). ALTERED MONOAMINE-MEDIATED BEHAVIORS FOLLOWING BICUCULLINE-INDUCED CONVULSIONS. BRIT J PHARMACOL. 70:P72-P73.
• COWEN PJ; GREEN AR; NUTT DJ. (1980). EFFECT OF ANESTHETIC ADMINISTRATION ON THE APPEARANCE OF ENHANCED MONOAMINE-MEDIATED BEHAVIORS FOLLOWING ELECTROCONVULSIVE SHOCK. BRIT J PHARMACOL. 70:P73-P74.

Conferences

• Nutt DJ. The role of neuroimaging in anxiety disorders. 21:S630-S630. (Sep 2011).
• Lees R; Williams T; Nutt D; Henderson G; Hickman M; Lingford-Hughes M. Comparison of a benzodiazepine and alcohol challenge in opioid dependent human participants. 21:S580-S581. (Sep 2011).
• Watson BJ; Taylor LG; Reid A; Wilson SJ; Stokes PR; Brooks DJ; Bose SK; Turkheimer F; et alLingford-Hughes AR; Nutt DJ. Investigating the effect of expectation on striatal dopamine release in heroin addicts: an C-11-raclopride PET study. 21:S320-S320. (Sep 2011).
• Carhart-Harris R; Erritzoe D; Stone J; Wise RG; Nutt D. The functional brain correlates of the psychedelic state: an arterial spin labelling study with psilocybin. 21:S313-S313. (Sep 2011).
• Nutt D. Setting the stage - Antidepressants. 21:S234-S235. (Sep 2011).
• Wilson SJ; Paterson LM; Durant CF; Sinclair L; Rich AS; Wood B; Lightman S; Nutt DJ; et alMalizia AL. ACUTE EFFECTS OF HIGH DOSE HYDROCORTISONE ON SLEEP IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION: A DOUBLE BLIND PLACEBO CONTROLLED STUDY. 25:A23-A23. (Aug 2011).
• Carhart-Harris RL; Erritzoe DE; Williams TM; Stone JM; Reed L; Tyacke R; Wise RG; Nutt DJ. DECREASED CEREBRAL BLOOD FLOW AFTER INTRAVENOUS PSILOCYBIN. 25:A39-A39. (Aug 2011).
• Mitchell EN; Marston H; Nutt DJ; Robinson ESJ. DIAZEPAM ATTENUATES THE INSTRUMENTAL SUCCESSIVE NEGATIVE CONTRAST EFFECT IN A PROGRESSIVE RATIO OPERANT MODEL. 25:A51-A51. (Aug 2011).
• Benecke A; Shotbolt JP; Egerton A; Nutt D; Lingford-Hughes AR; Howes O; Stokes PRA. DOES PRESYNAPTIC STRIATAL DOPAMINE SYNTHESIS CAPACITY PREDICT SOCIALLY DESIRABLE RESPONDING?. 25:A42-A42. (Aug 2011).
• Tyacke RJ; Durant CF; Paterson LM; Dineen P; Bachurova G; Wilson S; Nutt DJ; Malizia AL. EFFECTS OF ACUTE INHALATION OF VAPORIZED CANNABIS OR PLACEBO ON CARDIOVASCULAR AND SACCADIC EYE MOVEMENT MEASURES: A PILOT STUDY. 25:A37-A37. (Aug 2011).
• Quelch DR; Nutt DJ; Parker CA; Tyacke RJ. EFFECTS OF CELLULAR ENVIRONMENTS ON PET RADIOLIGAND BINDING - AN APPLICATION TO DOPAMINE AND OPIOID RECEPTOR IMAGING. 25:A60-A60. (Aug 2011).
• Nutt DJ. EVALUATING THE HUMAN HARMS AND POSSIBLE THERAPEUTIC USES OF ECSTASY. 25:A2-A2. (Aug 2011).
• Stokes PR; Clark L; Wu K; Michalczuk R; Watson B; Egerton A; Lappin J; Piccini P; et alNutt D; Bowden-Jones H; Lingford-Hughes A. IMAGING THE DOPAMINE SYSTEM IN PATHOLOGICAL GAMBLING: AN [11C]-RACLOPRIDE PET STUDY. 25:A61-A61. (Aug 2011).
• Stuart SA; Butler P; Nutt DJ; Robinson ESJ. INVESTIGATING AFFECTIVE STATE AND MEMORY USING A NOVEL RODENT ASSAY: IMPLICATIONS FOR THE CAUSE AND TREATMENT OF DEPRESSION. 25:A50-A50. (Aug 2011).
• Colasanti A; Searle GE; Long CJ; Hill SP; Reiley RR; Tziortzi AC; Quelch D; Gunn R; et alWaldman AD; Schruers KJ; Matthews PM; Nutt DJ; Rabiner EA. OPIOID RELEASE IN HUMAN BRAIN REWARD SYSTEM INDUCED BY AN ACUTE AMPHETAMINE CHALLENGE: A [11C]CARFENTANIL PET STUDY. 25:A60-A60. (Aug 2011).
• Lingford-Hughes A; Myers J; Wilson S; Stokes P; Taylor L; Watson B; Kalk N; Besson M; et alFeeney A; Rosso L; Turkheimer F; Cunningham VJ; Pike VW; Brooks DJ; Marshall EJ; Kerwin RW; Nutt DJ. THE GABA-BENZODIAZEPINE RECEPTOR, ITS SUBTYPES AND ALCOHOL MISUSE: INSIGHTS FROM IMAGING AND PHARMACOLOGICAL CHALLENGE STUDIES. 25:A79-A79. (Aug 2011).
• Diaper A; Bailey JE; Rich AS; Craig KJ; Dawson GR; Dourish CT; Nutt DJ. VENLAFAXINE AND PREGABALIN REDUCE CO2-INDUCED SYMPTOMS OF ANXIETY IN AN EXPERIMENTAL HUMAN MODEL. 25:A73-A73. (Aug 2011).
• Erritzoe D; Tziortzi A; Bargiela D; Searle G; Gunn RN; Beaver JD; Waldman A; Nutt D; et alBani M; Merlo-Pich E; Rabiner EA; Lingford-Hughes A. In Vivo Imaging of Dopamine D3 Receptors in Alcoholism Using Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist. 69:271S-271S. (1 May 2011).
• Quelch DR; Tyacke RJ; Nutt DJ; Parker CA. Assessment of cellular environments on radioligand binding - an application to opioid receptor PET imaging. 21:S7-S8. (Mar 2011).
• Paterson LM; Nutt DJ; Knudsen GM. A critical review of studies measuring endogenous 5-HT release by emission tomography. 52:S107-S107. (Aug 2010). DOI.
• Mitchell EN; Marston H; Nutt D; Robinson ESJ. Acute anxiolytic drug treatment has no effect on the instrumental successive negative contrast effect using a modified forced choice serial reaction time task. 20:S536-S536. (Aug 2010).
• Christmas D; Davies SJC; Hince DA; Williams J; Schroeder K; Nutt DJ. Day 3&7 jitteriness symptoms predict poor 6 week outcome in SSRI treatment and correlate with day 7 nocturnal activity. 20:S544-S545. (Aug 2010).
• Attwood AS; Bailey JE; Nutt DJ; Ataya AF; Munafo MR. Effects of nicotinised and denicotinised cigarette smoking on response to 7.5% carbon dioxide anxiety challenge. 20:S591-S591. (Aug 2010).
• Attwood AS; Bailey JE; Nutt DJ; Ataya AF; Munafo MR. EFFECTS OF NICOTINIZED AND DENICOTINIZED CIGARETTE SMOKING ON RESPONSE TO 7.5% CARBON DIOXIDE ANXIETY CHALLENGE. 24:A75-A75. (Aug 2010).
• Lingford-Hughes AR; Watson B; Daglish MR; Reid A; Williams TM; Wilson SJ; Taylor LG; Stokes P; et alNutt DJ. IMAGING THE ROLE OF DOPAMINE IN HUMAN OPIOID ADDICTS. 24:A8-A8. (Aug 2010).
• Mitchell EN; Marston H; Nutt D; Robinson ESJ. MANIPULATION OF ENVIRONMENTAL CONDITIONS ALTERS THE MAGNITUDE OF THE INSTRUMENTAL SUCCESSIVE NEGATIVE CONTRAST EFFECT IN RATS. 24:A77-A77. (Aug 2010).
• Stokes PRA; Shotbolt JP; Copeland C; Nutt D; Lingford-Hughes AR; Howes O. PREVIOUS COCAINE USE DECREASES PRESYNAPTIC LIMBIC DOPAMINERGIC FUNCTION: A [18F]-DOPA PET STUDY. 24:A57-A57. (Aug 2010).
• Quelch DR; Withey SL; Nutt DJ; Parker CA; Tyacke. SPECIES COMPARISON OF THE BINDING PROPERTIES FOR THREE D2/D3-DAR RADIOLIGANDS WIDELY USED IN PET IMAGING. 24:A33-A33. (Aug 2010).
• Kealey S; Husbands S; Casey EM; Salinas CA; Parker CA; Jakobsen S; Tyacke RJ; Nutt DJ; et alGee AD. Synthesis and in vivo evaluation of [11C]BU99008 as a ligand for the imidazoline 12 binding site. 52:S127-S128. (Aug 2010). DOI.
• Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ. THE ADMINISTRATION OF PSILOCYBIN TO HEALTHY HALLUCINOGEN-EXPERIENCED VOLUNTEERS IN A MOCK-FMRI ENVIRONMENT: A PRELIMINARY INVESTIGATION OF TOLERABILITY. 24:A60-A60. (Aug 2010).
• Myers JFM; Rosso L; Kalk NJ; Watson BJ; Wilson S; Brooks DJ; Nutt DJ; Turkheimer FE; et alLingford-Hughes AR. The effects of zolpidem on in vivo binding of [C11]-flumazenil and [C11]-Ro15-4513. 52:S191-S192. (Aug 2010). DOI.
• Nutt D. Treatments for generalised anxiety disorder: mechanism of action and clinical effect. 20:S639-S639. (Aug 2010).
• Fitz-Simon N; Lewis SJ; Smith GD; Zuccolo L; Sayal K; Draper ES; Fraser R; Barrow M; et alRing S; Golding J; Nutt DJ; Heron J; Gray R. Alcohol Consumption during Pregnancy and Children's Cognitive Development: Mendelian Randomization Study Using the ADH1B Genotype. 17:99A-100A. (Mar 2010).
• Maron E; Toru I; Hirvonen J; Vasar V; Shlik J; Nutt DJ; Tiihonen J; Hietala J. Brain serotonin transporter availability in panic disorder: Gender differences and implications for treatment response to escitalopram. 13:45-45. (2010).
• Quera-Salva MA; Hajak G; Keufer-Le Gall S; Nutt D. Efficacy and safety of agomelatine in patients with major depressive disorder compared to escitalopram: a randomized, double-blind study. 13:82-82. (2010).
• Watson BJ; Bowsher B; Wilson S; Taylor LG; Kalk NJ; Griffin L; Lingford-Hughes AR; Munafo M; et alNutt DJ. A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol dependent subjects. 19:S640-S640. (Sep 2009).
• Williams TM; Davies SJC; Taylor LG; Nutt DJ; Lingford-Hughes A. Association between opioid receptor availability and anxiety in healthy controls but not in substance dependence. 19:S653-S654. (Sep 2009).
• Nutt D. Clinical aspects of GABA. 19:S219-S219. (Sep 2009).
• Bell C; Potokar J; Hood S; Nash J; Frampton C; Hince D; Argyropoulos S; Nutt D. Do changes in 5HT function underlie CBT efficacy in panic disorder?. 19:S201-S201. (Sep 2009).
• Bailey JE; Phillips S; Diaper A; Rich A; Lightman S; Nutt DJ. Does the inhalation of CO2 activate neurosteroids in healthy participants? A pilot study. 19:S615-S616. (Sep 2009).
• Bailey JE; Diaper A; Rich AS; Dawson GR; Nutt DJ. Dose-dependent effects of a clinically effective and non-effective dose of lorazepam on 7.5% CO2-induced anxiety. 19:S609-S609. (Sep 2009).
• Paterson LM; Nutt DJ; Durant C; Wilson SJ. Efficacy of trazodone in primary insomnia; a double-blind randomised placebo controlled polysomnographic study. 19:S385-S386. (Sep 2009).
• Gallagher AM; de Vries F; Nutt DJ; Donoghue J; Tylee AT; Cockle SM; van Staa TP; Lader MH. Initiation of hypnotics or anxiolytics in depressed patients treated in UK primary care. 19:S379-S379. (Sep 2009).
• de Vries F; Gallagher AM; Lader MH; Tylee AT; Donoghue J; Cockle SM; van Staa TP; Nutt DJ. Insomnia as a predictor of depression in UK primary care. 19:S372-S373. (Sep 2009).
• Paterson L; Wilson SJ; Nutt DJ. NAtional Patient Sleep Assessment Questionnaire III (Napsaq-III) in depression; a survey for psychiatrists. 19:S388-S388. (Sep 2009).
• Tyacke RJ; Robinson ESJ; Harris A; Lingford-Hughes AR; Nutt DJ. Paradoxical effects of GABA on the in vivo uptake of the partial inverse GABA agonist [3H]Ro15-4513 in rat brain. 19:S276-S277. (Sep 2009).
• Gallagher AM; de Vries F; Donoghue J; Nutt DJ; Tylee AT; Cockle SM; van Staa TP; Lader MH. Persistence with hypnotics in depressed patients treated in UK primary care. 19:S380-S381. (Sep 2009).
• Davies SJC; Bjerkeset O; Jackson PR; Nutt DJ; Lewis G. Quadratic relation of frequent panic attacks with systolic blood pressure - the HUNT study. 19:S595-S596. (Sep 2009).
• Gallagher AM; de Vries F; Nutt DJ; Donoghue J; Tylee AT; Cockle SM; van Staa TP; Lader MH. Resource use in depressed patients with sleep disturbance. 19:S378-S379. (Sep 2009).
• Bailey JE; Rich A; Wilson S; Nutt DJ. The cardiovascular effects of a subtype selective and non-selective benzodiazepine agonist in healthy volunteers. 19:S606-S607. (Sep 2009).
• Gallagher AM; de Vries F; Tylee AT; Lader MH; Donoghue J; Cockle SM; van Staa TP; Nutt DJ. The risk of suicide and suicidal ideation in depressed patients with sleep disturbance. 19:S379-S380. (Sep 2009).
• Nutt D. WHAT WE KNOW AND WHAT WE DON'T KNOW ABOUT HOW NEUROLEPTICS WORK?. 80:817-817. (Jul 2009).
• Nutt D. Antidepressant pharmacotherapy-2009 and beyond. 19:S108-S109. (Apr 2009).
• Christmas D; Wilson S; Diaper A; Rich A; do Haes JU; Sjogren M; Nutt D. A double-blind, placebo-controlled, parallel group study of the effect of Org 25935 on cognitive performance. 19:S64-S65. (Mar 2009).
• Durant C; Wilson S; Paterson L; Nutt D; Gill S; Patel N; Malizia A. Sleep changes during deep brain stimulation for treatment resistant depression: preliminary findings from a case study. 19:S67-S68. (Mar 2009).
• Dickens R; Jessop D; Lightman S; Nutt D; Wilson S. Morning cortisol response in patients with parasomnia and insomnia. 17:193-193. (Dec 2008).
• Paterson LM; Nutt DJ; Wilson SJ. NAPSAQ II; national patient sleep assessment questionnaire in depression; a survey for general practitioners. 17:260-260. (Dec 2008).
• Green A; Hicks J; Nutt D; Wilson S. Perception of drug treatment in patients with chronic insomnia. 17:193-194. (Dec 2008).
• Durant CF; Wilson SJ; Paterson LM; Nutt DJ; Gill SS; Patel NK; Malizia AL. Sleep changes associated with mood improvement during acute deep brain stimulation of two different brain targets for treatment resistant depression. 17:259-260. (Dec 2008).
• Phillips S; Lightman S; Nutt D; Wilson S. Sleep stages and automatic overnight cortisol sampling. 17:228-228. (Dec 2008).
• Paterson LM; Nutt DJ; Wilson SJ. A national patient sleep assessment questionnaire in depression (NAPSAQ II); a survey for general practitioners. 18:S342-S342. (Aug 2008).
• Nutt DJ. Can neurobiology guide the choice of treatment?. 18:S599-S599. (Aug 2008).
• Williams TM; Davies SJC; Taylor LG; Daglish MR; Nutt DJ; Lingford-Hughes A. Can personality traits elucidate the relationship between substance dependence and opioid receptor availability?. 18:S536-S536. (Aug 2008).
• Tyacke RJ; Reid RHA; Grant EJ; Henry B; Zelaya F; Reul JMHM; Lightman S; Williams SCR; et alNutt DJ; Malizia AL. Hydrocortisone induces limbic, hippocampal and limbic/paralimbic cerebral perfusion changes as measured by 3T blood oxygenation level dependent (BOLD) phMRI. 18:S269-S269. (Aug 2008).
• Wilson SJ; Dickens R; Jessop D; Lightma SL; Nutt DJ. Morning cortisol response in patients with parasomnias and insomnia. 18:S584-S584. (Aug 2008).
• Brunello N; Bettica P; Amato D; Maier G; Nutt D. Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. 18:S581-S582. (Aug 2008).
• Bailey JE; Papadopoulos A; Diaper A; Phillips S; Schmidt M; van der Ark P; Dawson G; Nutt DJ. Preliminary evidence of efficacy of a CRF1 receptor antagonist in the 7.5% CO2 model of anxiety. 18:S494-S494. (Aug 2008).
• Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt D; Metspalu A. Serotonin transporter promoter polymorphism does not influence treatment response to escitalopram in depression. 18:S331-S331. (Aug 2008).
• Wilson S; Phillips S; Lightman SL; Nutt DJ. Sleep stages and automatic overnight cortisol sampling. 18:S584-S585. (Aug 2008).
• Nutt D. Brain circuits and insomnia: role of GABA. 11:315-316. (Jul 2008).
• Nutt D. GABA-(A) receptor subtypes as a target for anxiolytic drugs. 11:73-73. (Jul 2008).
• Nutt D. Multiple acting agents in depression. 11:52-52. (Jul 2008).
• Hood S; Melichar J; Taylor L; Daglish M; Holmes RB; Parkin VJ; Rees M; Kalk N; et alLenox-Smith A; Lingford-Hughes A; Nutt D. Noradrenergic function in generalised anxiety disorder (GAD): A single photon emission tomography (SPET) study. 11:278-278. (Jul 2008).
• Nutt D. GABA-A receptor inverse agonists as alcohol antagonists: the first human study. 42:313-313. (Jun 2008).
• Kerr JR; Petty R; Burke B; Gough J; Fear D; Sinclair LI; Mattey DL; Richards SCM; et alMontgomery J; Baldwin DA; Kellam P; Harrison TJ; Griffin GE; Main J; Enlander D; Nutt DJ; Holgate ST. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. 197:1171-1184. (15 Apr 2008). DOI.
• Carhart-Harris R; Nutt DJ; Munaf M; Wilson SJ. Current and former ecstasy users report different sleep to matched controls: a web based questionnaire study. 18:S66-S67. (Mar 2008).
• Parker CA; Tyacke RJ; Rabiner EA; Salinas CA; Gunn RN; Richards SN; Rosalki J; Gee AD; et alJakobsen S; Greedy B; Husbands SM; Slifstein M; Nutt DJ; Laruelle M. [C-11](+)RX-821024: A novel tracer for imaging alpha(2)-adrenoceptors. 41:T98-T98. (2008).
• Christmas D; Davies S; Sinclair L; Hood S; Potokar J; Srivastava S; Nutt D. A systematic review of antidepressant induced jitteriness/anxiety syndrome. 17:S353-S353. (Oct 2007).
• Hoodl S; Hince DA; Robinson H; Christmas D; Nutt DJ. Acute tryptophan depletion increases plasma prolactin in women but not men. 17:S336-S337. (Oct 2007).
• Williams TM; Lingford-Hughes A; Davies SJC; Daglish MRC; Taylor LG; Hammers A; Brooks DJ; Grasby P; et alMyles JS; Nutt DJ. Increased opioid receptor binding in early abstinence from dependent opioid and alcohol use and relationship to craving. 17:S187-S188. (Oct 2007).
• Nutt DJ; Mandel F; Baldinetti F. Rapid onset anxiolitic efficacy after a single dose of pregabalin: evaluation using dental anxiety model. 17:S503-S503. (Oct 2007).
• Paterson LM; Dinotaro KD; Nutt DJ; Wilson SJ. Sleep disturbance in depression: results from a UK survey. 17:S320-S320. (Oct 2007).
• Tyacke RJ; Reid A; Holmes R; Grant E; Zelaya F; Reul JMHM; Lightman S; Williams SCR; et alNutt DJ; Malizia AL. Subjective effects of acute dose of hydrocortisone in healthy volunteers. 17:S288-S289. (Oct 2007).
• Papadopoulos A; Bailey JE; Rich A; Nutt DJ. The further development of a new model of GAD: I - the effects of single dose alprazolam and zolpidem. 17:S521-S522. (Oct 2007).
• Bailey JE; Papadopoulos A; Rich A; Nutt DJ. The further development of a new model of GAD: II - The effects of single dose anxiolytic medication. 17:S520-S521. (Oct 2007).
• Bailey JE; Phillips SM; Papadopoulos A; Diaper A; Rich A; Tyacke RJ; Seddon K; Nutt DJ. The further development of a new model of GAD: no effect of 7.5% CO2 on HPA axis activation in healthy volunteers. 17:S521-S521. (Oct 2007).
• Nutt D; Bailey J; Papadopoulos A. Validation of CO2 stress test in humans. 17:S194-S194. (Oct 2007).
• Steckler T; den Boer JA; Nutt D; Van Laere K; Langlois X; Warnock G; Drinkenburg WHIM; Schmidt M. Translational models of anxiety disorders for drug discovery and development. 18:S110-S110. (Sep 2007).
• Nutt DJ. Validation studies on CO2 models of anxiety in normal volunteers. 61:197S-198S. (15 Apr 2007).
• Williams TM; Lingford-Hughes A; Daglish MRC; Taylor LG; Hammers A; Brooks DJ; Grasby P; Nutt DJ. Increased opiold receptor binding in early abstinence from dependent opioid and alcohol use and relationship to craving. 17:S78-S79. (Mar 2007).
• Papadopoulos A; Bailey JE; Nutt DJ. The effects of C-cycloserine on a cognitive task under different states of anxiety. 17:S37-S37. (Mar 2007).
• Davies SJ; Jackson PR; Lewis G; Hood SD; Nutt DJ; Potokar JP. Panic attacks more likely to include autonomic symptoms in patients with hypertension than in normotensives - A comparison of symptoms, and factor analysis. 31:S231-S231. (Dec 2006).
• Bailey JE; Papadopoulos A; Nutt DJ. A pooled analysis of the effects of 7.5% CO2 inhalation in healthy participants: a useful model of human anxiety?. 16:S474-S474. (Sep 2006).
• Nutt D. Assessing the noradrenalin system in humans. 16:S206-S206. (Sep 2006).
• Argyropoulos SV; Hood SD; Davies SJC; Hince DA; Morris K; Nutt DJ; Potokar JP. Dopaminergic challenges in social anxiety disorder. 16:S186-S186. (Sep 2006).
• Paterson L; Ivarsson M; Hutson P; Nutt DJ; Wilson SJ. Effects on sleep of caffeine and its combination with trazodone or zolpidem in healthy volunteers. 16:S551-S551. (Sep 2006).
• Nutt D. Evolving therapy for managing depression: a brief look into the future. 16:S591-S591. (Sep 2006).
• Davies SJC; Hood SD; Argyropoulos SV; Hince DA; Morris K; Nutt DJ; Potokar J. Serotonin reuptake inhibition and dopamine receptor antagonism together buffer the blood pressure response to stress in social anxiety disorder. 16:S458-S458. (Sep 2006).
• Hood SD; Argyropoulos SV; Davies SJC; Hince DA; Bell CJ; Nutt DJ; Potokar J. The effect of acute tryptophan depletion on challenge induced anxiety in anxiety disorder patients is independent of a history of depression. 16:S473-S474. (Sep 2006).
• Bailey JE; Papadopoulos A; Nutt DJ. The effects of D-cycloserine on a cognitive function task under different states of anxiety in healthy volunteers. 16:S457-S458. (Sep 2006).
• Paterson L; Ivarsson M; Hutson P; Nutt DJ; Wilson SJ. Validation of a translational model of insomnia in rats and human volunteers. 16:S550-S550. (Sep 2006).
• Paterson LM; Wilson SJ; Nutt DJ; Hutson PH; Ivarsson M. Validation of a translational model of insomnia in rats and human volunteers. 15:38-38. (Sep 2006).
• Nutt DJ. Modelling anxiety disorders in human volunteers. 16:S86-S86. (Mar 2006).
• Davies S; Jackson PR; Lewis G; Hood S; Nutt DJ. Panic attacks are more likely to include autonomic symptoms in patients with hypertension than in normotensives - a comparison of symptoms, and factor analysis. 16:S94-S94. (Mar 2006).
• Papakostas GI; Nutt DJ; Tucker VL; Krishen A; Fava M. Resolution of sleepiness and fatigue in the treatment of major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. 30:S186-S187. (Dec 2005).
• Bailey S; Zhang Z; Nutt DJ. 5-HT1A receptor activation induces upregulation of GABAAR gene expression in neurones. 15:S530-S531. (Oct 2005).
• Toru I; Shlik J; Maron E; Vasar V; Nutt DJ. Acute tryptophan depletion does not modify the response to cck-4 challenge in patients with panic disorder after citalopram treatment. 15:S555-S556. (Oct 2005).
• Davies SJC; Hood SD; Argyropoulos SV; Morris K; Bell CJ; Witchel HJ; Jackson PR; Nutt DJ; et alPotokar J. Depleting brain serotonin enhances both cardiovascular and psychological responses to stress in recovered patients with anxiety disorders. 15:S536-S536. (Oct 2005).
• Daglish M; Lingford-Hughes AR; Grasby PG; Brooks DJ; Nutt DJ. Does heroin release dopamine? A positron emission tomography study. 15:S341-S341. (Oct 2005).
• Lingford-Hughes AR; Daglish M; Brooks DJ; Nutt DJ. Imaging brain opioid receptors in alcohol and heroin dependence. 15:S331-S331. (Oct 2005).
• Bailey JE; Kendrick AH; Diaper A; Nutt DJ. The 7.5% CO2 model of anxiety: effects of anxiolytic medication on psychological and physiological measures. 15:S548-S548. (Oct 2005).
• Welch S; Lingford-Hughes AR; Nutt DJ. Treatment of nicotine dependence and cocaine addiction. 15:S361-S362. (Oct 2005).
• Wilson SJ; Besson M; Lingford-Hughes A; Dawson GR; Nutt DJ. Antagonisinc alcohol's actions by an inverse agonist at alpha 5 subtype GABA(A) receptors in humans. 19:A24-A24. (Sep 2005).
• Bailey JE; Nutt DJ. Are personality factors related to the CO2 response in healthy volunteers?. 19:A18-A18. (Sep 2005).
• Anderson NJ; Nutt DJ; Hudson AL; Robinson ESJ. C-fos activation in rat brain following administration of imidazoline binding site and monoamine oxidase ligands. 19:A38-A38. (Sep 2005).
• Davies SJC; Hood SC; Argyropoulos SV; Morris K; Bell CJ; Witchel HJ; Jackson PR; Nutt DJ; et alPotokar J. Depleting brain 5HT enhances both cardiovascular and psychological stress reactivity in humans. 19:A20-A20. (Sep 2005).
• Anderson NJ; Tyacke RJ; Husbands SM; Nutt DJ; Hudson AL; Robinson ESJ. Distribution of the endogenous B-carboline, harmane, in rat brain. 19:A38-A38. (Sep 2005).
• Man J; Geys H; Hudson AL; Nutt DJ; Ashton D. Further validation of the quinpirole-induced compulsive checking paradigm as a model for obsessive-compulsive disorder (OCD)-restraint stress exacerbates some compulsive checking measures. 19:A16-A16. (Sep 2005).
• Bailey JE; Kendrick A; Diaper A; Nutt DJ. The effects of lorazepam and paroxetine on the 7.5% CO2 model of anxiety. 19:A18-A18. (Sep 2005).
• Potokar J; Shufflebotham J; Hood S; Hendry J; Rich A; Probert C; Nutt D. Tryptophan depletion in irritable bowel syndrome patient subgroups. 19:A20-A20. (Sep 2005).
• Davies S; Hood S; Argyropoulis S; Bell C; Jackson P; Nutt D; Potokar J. Hypertension and anxiety - Serotonin depletion associated with consistent excess pressor response to stress challenge in patients with treated anxiety disorders. 23:S139-S139. (Jun 2005).
• Zhang Z; Nutt DJ; Bailey SJ. 5-HT1A receptor activation induces upregulation of GABA(A)R gene expression in neurones. 15:S27-S27. (Mar 2005).
• Ignjatovic D; Ignjatovic M; Nutt DJ. Pharmacological treatment of late-life depression. 38:53-54. (Jan 2005).
• Nash JR; Sargent PA; Rabiner EA; Hood SD; Argyropoulos S; Grasby PM; Nutt DJ. Altered 5HT1A binding in panic disorder demonstrated by positron emission tomography. 14:S322-S323. (Oct 2004).
• Nutt DJ; Bailey JE. Can CO2 be used to model different anxiety disorders?. 14:S153-S154. (Oct 2004).
• Nutt DJ. Generalized anxiety disorder: A comorbid disease. 14:S411-S412. (Oct 2004).
• Melichar JK; Heath T; Jackson LN; Watson B; Nutt DJ; Donaldson LF. Serotonin and the 5HT(1A) receptor in the signalling of taste: A novel human surrogate marker?. 14:S225-S226. (Oct 2004).
• Law FD; Myles JS; Daglish MRC; Nutt DJ. The clinical use of buprenorphine in opiate addiction: evidence and practice. 16:246-274. (Oct 2004).
• Hood SD; Argyropoulos SV; Potokar J; Bell CJ; Shufflebotham J; Rich AS; Nutt DJ. A meta-analysis of acute tryptophan depletion studies in anxiety disorders using individual patients' data. 18:A22-A22. (Sep 2004).
• Linford-Hughes AR; Davies SJC; Taylor LG; Williams TM; Daglish MRC; Pandit S; Hammers A; Brooks DJ; et alNutt DJ. A PET study of opioid receptors in abstinent alcohol dependent patients. 18:A41-A41. (Sep 2004).
• Anderson NJ; Lupo PA; Nutt DJ; Hudson AL; Robinson ESJ. Brain 12 binding does not correspond to monoamine oxidase A or B populations across five species. 18:A34-A34. (Sep 2004).
• Man J; Willems R; Hudson A; Nutt D; Ashton D. Chronic quinpirole-induced compulsive checking in rats - What is the temporal distribution of compulsive checking parameters?. 18:A30-A30. (Sep 2004).
• Wilson SJ; Bailey JE; Rich AS; Nutt DJ. Dizziness after 5HT(1A) receptor agonists is not due to postural hypotension. 18:A20-A20. (Sep 2004).
• Lingford-Hughes AR; Hayward RC; Mill J; Ball D; Nutt DJ. Dopamine receptor genotypes in non-dependent and dependent smokers. 18:A30-A30. (Sep 2004).
• Hood SD; Nash JR; Bell CJ; Hurst J; Adrover MDM; Pyle AC; Rich AS; Slattery HL; et alPotokar JP; Nutt DJ. Early results from a tryptophan depiction study in panic disorder patients treated with cognitive behavioural therapy. 18:A22-A22. (Sep 2004).
• Abu Ghazaleh H; Lalies M; Nutt DJ; Hudson AL. In vitro [3H]harmane (1-methyl-(beta)-carboline) uptake in the rat cortex. 18:A31-A31. (Sep 2004).
• Tyacke RJ; Robinson ESJ; Hume S; Nutt DJ; Hudson AL. Is P-glycoprotein responsible for the poor brain accumulation of the potential pet ligand BU97001 in rat brain?. 18:A35-A35. (Sep 2004).
• Bailey JE; Rich N; Wilson SJ; Nutt DJ. Subjective ratings in volunteer populations: Two methods, same task, different outcome. 18:A20-A20. (Sep 2004).
• Bailey JE; Kendrick A; Wilson SJ; Nutt DJ. The effects of the CO2 challenge on a novel group performance task. 18:A46-A46. (Sep 2004).
• Nutt D. Anxiety and depression: individual entities or two sides of the same coin?. 8:19-24. (Aug 2004). DOI.
• Daglish MRC; Lingford-Hughes AR; Nutt DJ. Brain imaging alcohol cue-reactivity. 28:65A-65A. (Aug 2004).
• Hood SD; Argyropoulos S; Potokar J; Bell C; Shufflebotham J; Nutt DJ. A meta-analysis of acute tryptophan Depletion studies in anxiety disorders using individual patients' data. 7:S194-S194. (Jun 2004).
• Nutt D. Imaging receptors in human anxiety. 7:S17-S17. (Jun 2004).
• Tyacke R; Robinson E; Hudson A; Nutt D; Lingford-Huges A. Effects of endogenous noradrenaline on the in vivo binding of [H-3]2-methoxyidazoxan ([H-3]RX821002) in rat brain. 22:T94-T95. (2004).
• Nash JR; Sargent PA; Rabiner EA; Hood SD; Argyropoulos SV; Grasby PM; Nutt DJ. Altered 5HT(1A) binding in panic disorder demonstrated by PET scanning. 17:A30-A30. (Sep 2003).
• Nutt DJ; Nash JR; Bell C; Adrover M; Sargent PA; Rabiner EA; Hood S; Argyropoulos S; et alGrasby R. Antidepressant mechanisms in anxiety disorders. 13:S173-S173. (Sep 2003).
• Anderson NJ; Robinson ESJ; Husbands S; DeLagrange P; Nutt DJ; Hudson AL. Characterisation [H-3]harman binding to rat whole brain membranes. 17:A39-A39. (Sep 2003).
• Wilson SJ; Bailey JE; Rich AS; Tournoux A; Nutt DJ. Effects of 5HT(1A) agonists on sleep in normal volunteers: a comparison of eptapirone, buspirone, and placebo. 17:A73-A73. (Sep 2003).
• Cambridge NJ; Edwards ME; Nutt DJ; Hudson AL; Robinson ESJ. Effects of BU98008, a novel I-1-binding site ligand, on food intake in rats. 17:A74-A74. (Sep 2003).
• Melichar JK; Witchel HJ; Taylor LG; Lingford-Hughes AR; Nutt DJ. Heart rate variability (HRV) and noradrenergic dysfunction in generalised anxiety disorder (GAD): Assessment using a clonidine challenge. 17:A29-A29. (Sep 2003).
• Kimura A; Tyacke RJ; Minchin MCW; Nutt DJ; Hudson AL. Identification of a 55kDa imidazoline-2 binding protein in rabbit brain. 17:A38-A38. (Sep 2003).
• Paterson LM; Robinson ESJ; Nutt DJ; Hudson AL. In vivo estimation of I-2 binding site turnover in rat brain. 17:A39-A39. (Sep 2003).
• Tyacke RJ; Westaway J; Grella B; Glennon RA; Nutt DJ; Hudson AL. Initial evaluation of two novel beta-carbolines for rat brain imidazoline(2) binding sites. 17:A39-A39. (Sep 2003).
• Nutt DJ. Opiate partial agonists. 17:A3-A3. (Sep 2003).
• Paterson L; Tyacke RJ; Robinson ESJ; Nutt DJ; Hudson AL. Role of monoamine oxidase in imidazoline(2) binding site mediated function in rat brain. 13:S104-S105. (Sep 2003).
• Shufflebotham J; Hendry J; Rich A; Probert C; Nutt D; Potokar J; Hood S. Tryptophan depletion study in irritable bowel syndrome (IBS). 17:A17-A17. (Sep 2003).
• Kimura A; Tyacke RJ; Minchin MCW; Nutt DJ; Hudson AL. Identification of a putative imidazoline-2 binding protein. 138:U87-U87. (Apr 2003).
• Daglish MRC; Nutt DJ. Brain imaging studies in human addicts. 13:S7-S9. (Mar 2003).
• Williams TM; Daglish MRC; Lingford-Hughes A; Hammers A; Brooks DJ; Myles JS; Nutt DJ. Regional cerebral increases in opioid receptor density in early abstinence from methadone: a PET study in man. 13:S31-S31. (Mar 2003).
• Bailey JE; Nash J; Argyropoulos SV; Nutt DJ. 7.5% CO2: A model of GAD?. 16:A51-A51. (Sep 2002).
• Williams TM; Daglish MRC; Lingford-Hughes A; Hammers A; Brooks DJ; Myles JS; Nutt DJ. Altered brain opioid receptor density after withdrawal from methadone treatment. 16:A54-A54. (Sep 2002).
• Anderson NJ; Nutt DJ; Hudson AL; Robinson ESJ. Characterisation of imidazoline(2) binding in pig brain. 16:A64-A64. (Sep 2002).
• Bailey JE; Argyropoulos SV; Nash J; Lightman SL; Nutt DJ. Does the locus coeruleus mediate the effects of the CO2 challenge?. 16:A52-A52. (Sep 2002).
• Adrover M; Nash J; Rich A; Nutt DJ; Potokar J. Effects of abstinence from alcohol in social drinkers on GABA(A) benzodiazepine receptor (GBzR) sensitivity. 16:A56-A56. (Sep 2002).
• Daglish MRC; Weinstein A; Malizia AL; Wilson S; Melichar JK; Lingford-Hughes A; Myles JS; Grasby P; et alNutt DJ. Functional connectivity analysis of rCBF in opiate craving. 16:A55-A55. (Sep 2002).
• Tyacke RJ; Davis N; Nutt DJ; Hudson AL. Initial evaluation of four potential imidazoline(2) pet ligands in rat whole brain. 16:A63-A63. (Sep 2002).
• Man J; Tyacke RJ; Saczewski F; Nutt DJ; Hudson AL. Initial evaluation of three novel selective ligands of imidazoline-2 receptors in rat whole brain. 16:A63-A63. (Sep 2002).
• Kimura A; Tyacke RJ; Nutt DJ; Hudson AL. Microautoradiography of imidazoline-2 binding sites in rabbit hypothalamus. 16:A63-A63. (Sep 2002).
• Melichar JK; Taylor LG; Daglish MRC; Holmes RB; Parkin VJ; Rees MR; Lenox-Smith A; Lingford-Hughes AR; et alNutt DJ. Noradrenergic dysfunction in generalised anxiety disorder (GAD): A SPET study using a clonidine challenge. 16:A52-A52. (Sep 2002).
• Wilson SJ; Bailey JE; Nutt DJ. Probing serotonergic activity in the brain using sleep. 16:A41-A41. (Sep 2002).
• Nutt DJ. The drug treatment of PTSD. 16:A5-A5. (Sep 2002).
• Paterson LM; Tyacke RJ; Nutt DJ; Hudson AL. The irreversible I-2 ligand BU99006 abolishes [H-3]2BFI binding without effect on monoamine oxidase activity. 16:A63-A63. (Sep 2002).
• Argyropoulos SV; Adrover M; Hood SD; Bell CJ; Rich AS; Nash JR; Rich NC; Nutt DJ. Tryptophan depletion in treated social anxiety disorder: effects of autobiographical scripts and stressful speaking tasks. 16:A51-A51. (Sep 2002).
• Wilson SJ; Bailey JE; Rich AS; Adrover M; Nutt DJ. Using sleep to measure relative 5HT uptake blockade. 16:A41-A41. (Sep 2002).
• Nutt DJ. Brain imaging in anxiety disorders. 17:S1-S1. (Aug 2002).
• Witchel HJ; Bell C; Mazzeo L; Hennessy E; Nash J; Argyropoulos S; Adrover M; Rich A; et alPotokar J; Wilson SJ; Nutt DJ. Paroxetine-remitted panic patients on a tryptophan depletion diet have a higher change in blood pressure and heart rate in response to either flumazenil or saline infusions than when not tryptophan depleted: a regression analysis. 536:145P-145P. (Nov 2001).
• Argyropoulos SV; Nutt DJ. The use of benzodiazepines in anxiety and other disorders. 9:407-412. (Dec 1999).
• Nutt DJ. The neurochemistry of addiction. 12:S53-S58. (Jun 1997).
• Nutt DJ. Receptor pharmacology of buprenorphine. 19:9-15. (1997).
• Nutt D; Montgomery SA. Moclobemide in the treatment of social phobia. 11:77-82. (Jun 1996).
• Nutt D. The changing pharmacology of addiction. 33-49. (1994).
• NUTT D; LALIES M; HUDSON A. THE EFFECTS OF ALPHA(2)-ADRENOCEPTOR ANTAGONISTS ON EXTRACELLULAR DOPAMINE CONCENTRATIONS IN RAT STRIATUM. 159-172. (1994).
• NUTT D. OVERVIEW - UNANSWERED QUESTIONS AND CLINICAL PROSPECTS. 59:205-211. (1993).
• NUTT DJ; HOLMAN RB; THOMAS DN. NORADRENERGIC MECHANISMS IN ANXIOLYTIC AND ANTIDEPRESSANT DRUG-ACTION. 101-116. (1992).
• NUTT DJ. THE CRITICAL ISSUES IN BENZODIAZEPINE TOLERANCE AND WITHDRAWAL. 3:74-77. (1992).
• HUDSON AL; MALLARD NJ; NUTT DJ. [3H]RX821002 - A NEW ALPHA-2-ADRENOCEPTOR LIGAND FOR INVITRO AUTORADIOGRAPHY AND BINDING-STUDIES IN THE MAMMALIAN CNS. 299-300. (1991).
• NUTT DJ. ANXIETY AND ITS THERAPY - TODAY AND TOMORROW. 4:1-12. (1991).
• HOLMAN RB; THOMAS DN; NUTT DJ. NEW INSIGHTS INTO THE NEUROBIOLOGY OF ECT - REGIONALLY SELECTIVE ALTERATIONS IN NORADRENALINE RELEASE REVEALED BY MICRODIALYSIS. 968:268-271. (1991).
• NUTT DJ. BENZODIAZEPINE DEPENDENCE - NEW INSIGHTS FROM BASIC RESEARCH. 19-41. (1990).